WO1990006696A2 - Meningococcal class 1 outer-membrane protein vaccine - Google Patents

Meningococcal class 1 outer-membrane protein vaccine Download PDF

Info

Publication number
WO1990006696A2
WO1990006696A2 PCT/US1989/005678 US8905678W WO9006696A2 WO 1990006696 A2 WO1990006696 A2 WO 1990006696A2 US 8905678 W US8905678 W US 8905678W WO 9006696 A2 WO9006696 A2 WO 9006696A2
Authority
WO
WIPO (PCT)
Prior art keywords
class
protein
vaccine
meningococcal
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1989/005678
Other languages
French (fr)
Other versions
WO1990006696A3 (en
Inventor
Robert C. Seid, Jr.
Peter R. Paradiso
Jan T. Poolman
Peter Hoogerhout
Emmanuel J. H. J. Wiertz
Peter Van Der Ley
John Edward Heckels
Ian Nicholas Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIJKINSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEUHY GINE
Wyeth Holdings LLC
Original Assignee
RIJKINSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEUHY GINE
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27352237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1990006696(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8803111A external-priority patent/NL8803111A/en
Application filed by RIJKINSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEUHY GINE, Praxis Biologics Inc filed Critical RIJKINSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEUHY GINE
Priority to EP90901397A priority Critical patent/EP0449958B9/en
Priority to JP50166290A priority patent/JP3436756B2/en
Priority to DE68921895T priority patent/DE68921895T3/en
Publication of WO1990006696A2 publication Critical patent/WO1990006696A2/en
Publication of WO1990006696A3 publication Critical patent/WO1990006696A3/en
Priority to DK199101174A priority patent/DK175788B1/en
Priority to NO912369A priority patent/NO305463B1/en
Priority to FI912965A priority patent/FI113009B/en
Anticipated expiration legal-status Critical
Priority to US08/204,808 priority patent/US7118757B1/en
Priority to US08/461,651 priority patent/US7238345B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Definitions

  • Bacterial meningitis is an inflammatory disease of the central nervous system caused by the growth of bacteria in and adjacent to the leptomeninges. Meningitis is an acute infectious disease which affects children and young adults and is caused by the Neisseria meningitidis, amongst other agents including other bacterial and viral pathogens.
  • Meningococci are subdivided into serological groups depending on the presence of either capsular or cell wall antigens.
  • sero- groups include A, B, C, D, W-135, X, Y, Z, and 29E as segregated by seroagglutination.
  • the polysaccharides responsible for the serogroup specificity of the group A, B, C, X, W-135 and Y have been purified.
  • the carrier rate for meningococci is much higher than the incidence of the disease. Some persons are temporary carriers, while others are chronic carriers, discharging meningococci either more or less continuously or in a sporadic fashion.
  • the meningococcal carrier state is an immunizing process, and within two weeks of colonization, production of antibodies to meningococci can be identified. It appears that bactericidal antibodies are directed against both the capsular polysaccharide and other cell wall antigens. Studies have shown that meningococcal outer membranes have three to five major proteins, with the predominant 41,000Mr or 38,000Mr proteins carrying the serotype specific determinants.
  • the capsular polysaccharide of groups A, C, W-135 and Y meningococci have been used to develop vaccines against the organism. Although these vaccines have been effective in the short term, they do not induce immunological memory and subjects must be revaccinated within approximately 3 years to maintain their resistance.
  • the group B polysaccharide is poorly immunogenie and successful vaccines have not been produced. A possible explanation for the low activity may be due to tolerance to the group B polysaccharide induced by crossreactive antigens found in human tissues such as the brain. Furthermore, studies show that most of the bactericidal antibodies in the convelescent sera of patients who have had group B meningococcal disease are directed against outer membrane proteins.
  • Vaccines for protecting against group B meningococcal disease have been developed in which non-covalent complexes of outer membrane proteins (OMP) and group B polysaccharide were administered.
  • OMP outer membrane proteins
  • the isolated OMV's, meningococcal Class I OMP, fragments or oligopeptides derived therefrom can be used in univalent or multivalent subunit vaccines alone, in mixtures, or as chemical conjugates or genetic fusions. In preferred vaccines, epitopes from different epidemiologically relevant
  • meningococcal strains are used.
  • isolated OMV's, the Class I OMP, fragments or oligopeptides can be used in conjunction (as
  • N. meningitidis antigens of N. meningitidis.
  • they can be used in conjunction with capsular polymers or oligomers (or fragments thereof) of N. meningitidis or with Class I outer membrane proteins(or epitopes thereof) of different subtypes.
  • they can be used with antigens of other infectious bacteria, viruses, fungi or parasites.
  • Class I OMP T cell epitopes also are defined and these can be used in conjunction with other vaccine components to enhance the protective immune response to the vaccines.
  • This invention also pertains to the methods of producing isolated OMV's, the Class I OMP, fragments and oligopeptides and to various vaccine
  • the isolated OMV's Class I OMP can be produced by mutant meningococcal strains which do not express the Class 2/3 outer membrane protein. Fragments can be produced by cyanogen bromide cleavage and subsequent purification. Isolated OMV's, the Class I OMP, fragments or oligopeptides can be produced by recombinant DNA techniques, chemical synthesis or chemical or enzymatic cleavage. These materials, in turn, can be conjugated or fused to carrier peptides or proteins, to other antigens of N. meningitidis or to antigens of other microorganisms by chemical or genetic coupling techniques to produce multivalent antigenic conjugates and fusion peptides or
  • isolated OMV's, the class I OMP, fragments or oligopeptides, in any of the forms described can be formulated in pharmaceutically acceptable vehicles with optional additives such as adjuvants.
  • This invention also pertains to isolated nucleic acids which encode class I OMP, fragments or oligopeptides.
  • the nucleic acids can be incorporated into appropriate expression systems for production of isolated OMV's, Class I OMP, fragments or any oligopeptides derived therefrom.
  • These nucleic acids can be modified as genetic fusions to contain sequences encoding additional polypeptides useful in enhancing the immune response to the vaccine formulation containing the expressed fusion polypeptides.
  • Class I OMP of N. meningitidis is homologous in amino acid sequence and structure to porin proteins of other gram negative pathogens and thus the Class I OMP, fragments and oligopeptides of this invention allow for the development of vaccines for other gram negative pathogens.
  • Figure 1 Scheme for amplification of genes encoding meningococcal Class I outer membrane protein by PCR (Polymerase Chain Reaction).
  • Figure 7 Structure of recombinant flagellins expressing variabvle region epitopes of N.
  • Figure 8 Representative chromotogram of high performance liquid chromatography of a recombinant flagellin.
  • Figure 9 Representative analysis by SDS-PAGE of recombinant flagellin.
  • This invention pertains to vaccines comprising isolated OMV's, meningococcal Class 1 OMP, fragments of the OMP (e.g., prepared by the application of cyanogen bromide ) and oligopeptides bearing epitopes of the OMP; the preparation of isolated OMV's, pure Class 1 outer-membrane proteins, using mutant strains which do not express the Class 2/3 outer-membrane protein; the preparation of isolated OMV's pure Class 1 outer-membrane proteins with the aid of cloned DNA in recombinant DNA expression vectors.
  • This invention also comprises the application of genetic engineering with the object of producing isolated OMV's Class I OMP or portions thereof, genetic fusions of Class I OMP, portions or epitopes therof; and the preparation of multivalent Class 1 outer-membrane vaccine through peptide synthesis, as the epitopes with a short peptide chain can be synthetically prepared.
  • meningococcal Class 1 outer-membrane proteins induce a strong bactericidal immune response to the strains containing the appropriate subtype epitopes, irrespective of whether these are from group A, B , C , W- 135 , and Y strains.
  • the polysaccharide vaccine can be enhanced or replaced by a vaccine according to the invention as a vaccine with broad, extensive action against most serotypes.
  • the protective bactericidal monoclonal antibodies specific for the Class 1 outer--membrane protein react strongly with fragments that have been split off and short synthetic peptides which have been prepared using the amino acid sequence of Class 1 outer-membrane proteins.
  • vaccines of this invention which comprise one or more Class 1 OMP epitopes derived from N.
  • meningitidis group B should be effective in preventing disease caused by group A, C, W-135 and Y.
  • Vaccines according to the invention comprise, for example, at least one protein which is obtained either in OMV formulation or by purification from mutant strains producing one or more Class I OMP or at least two fragments prepared through a cyanogen bromide fragmentation or at least two synthetic peptides, chosen from about 10 major epitopes, or products obtained by gene expression via recombinant DNA technology, which contain the desired epitopes.
  • Vaccines according to the invention comprise, for example, at least one protein which is obtained either in OMV formulation or by purification from mutant strains producing one or more Class I OMP or at least two fragments prepared through a cyanogen bromide fragmentation or at least two synthetic peptides, chosen from about 10 major epitopes, or products obtained by gene expression via recombinant DNA technology, which contain the desired epitopes.
  • the greater number of different protective epitopes in the vaccine the better.
  • the vaccines according to the invention may advantageously contain meningococci A and C or optionally W-135 and Y polysaccharides and/or detergents.
  • the A and C polysacchar ides are convalently coupled to a protein or polypeptide carrier.
  • These carriers include, for example, isolated OMV, the Class I OMP protein, T-helper epitopes, bacterial toxins, toxoids, nontoxic mutants (CRM's), recombinant
  • Salmonella flagellin and viral particles such as rotavirus VP6 protein, Hepatitis B surface antigen or parvovirus VP1 and VP2 p ro te ins .
  • Bo th Zwi t te r i ono gen i c , c at iono genic, anionogenic and nonionogenic detergents can be used.
  • Examples of such detergents are Zwittergent 3-10, Zwittergent 3-14 (N-tetradecyl-N, N-dimethyl-3-ammonia-1-propane sulphonate), Tween-20, sodium deoxycholate, sodium cholate and octylglucoside.
  • the vaccines according to the invention may also contain an adsorbent such as aluminium hydroxide, calcium phosphate; or advantageously, aluminium phosphate.
  • an adsorbent such as aluminium hydroxide, calcium phosphate; or advantageously, aluminium phosphate.
  • the fragments, proteins, peptides can also be processed in immunostimulating complexes (ISCOMS), liposomes or
  • microspheres for delivering and/or use as an
  • This invention encompasses isolated OMV, substantially pure meningococcal class 1 outer membrane proteins (of any subtype) and fragments of the proteins containing epitopes thereof.
  • the fragments can be any portions of the molecular weight of 25kD or less which contain epitopes which are bound by protective bactericidal antibodies against N. meningitidis.
  • proteolytic fragments and synthetic oligopeptides which are comprised of amino acid sequences which correspond, at least in part, to epitopes of a Class I OMP.
  • the isolated OMV's, Class I OMP, fragments or epitope-containing oligopeptides derived therefrom can be comprised of amino acid sequences which are different, but essentially biologically equivalent to the natural sequences. These sequences can include sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
  • the nonp o l ar ( hydrophob ic ) amino acids include glycine, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar neutral amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic and glutamic acids.
  • isolated OMV's, the class I OMP, fragments or the oligopeptides can be modified for conjugation to other molecules (e.g., by the
  • coupling groups such as the amino acids cysteine and/or lysine or other linking groups and/or spacer groups
  • other class 1 OMP of a different subtype T cell epitopes, B cell
  • the Class I OMP. fragments or oligopeptides can be used in many different forms (e.g., alone, in mixtures, or as conjugates and genetic fusions produced from recombinant DNA vectors) in vaccines.
  • the materials can be produced by isolation from N. meningitidis, by proteolytic digestion, by chemical synthesis, or by expression as recombinant molecules.
  • the methods of production and use of the isolated OMV's, the class I OMP and the fragments and the oligopeptides of class 1 OMP are described below. Protein modeling and structure analysis of the Class I OMPs were performed using the principles for several E. coli outer membrane proteins. (Vogel, H. et al., J. Mol.
  • meningitidis and their structure one can predict based upon the amino acid sequence where protective epitopes may reside for other pathogenic gram negative bacteria to be evaluated and included in vaccines for the same.
  • OMV's can be produced either from the culture supernatant or from the bacterial cells after fragmentation as described by Beuvery et al. (1983) loc. cit.
  • OMV's carrying proteins from more than one meningococcus can be isolated from strains manipulated to express heterologous proteins. Production and Purification of Class I OMP and CNBr fragments thereof
  • Class 1 and Class 3 outer membrane proteins can be isolated as described by Beuvery, E.C. et al ., Antonie wan Leeuvenhoek J. Microbiol. 52: 232 (1986).
  • the production of substantially pure Class I OMP free of Class 2 or 3 OMP's is achieved by this method using mutant meningococcal strains which do not express Class 2/3 OMP.
  • a preferred strain for production of Class I OMP is the HIII5 strain, deposited as CBS 636.89.
  • Fragments can be produced by cyanogen bromide cleavage as described by Teerlink T. et al., J. Exp. Med . 166:63 (1987) for a gonococcal protein.
  • the N-terminal fragment is referred to as CB-1 and the C-terminal fragment is referred to as CB-2.
  • CNBr fragments can be purified via reverse phase
  • the fragment can be purified by multiple cold tr ichloroacetic acid precipitations. These procedures remove greater than 95% of interferring contaminants (e.g., buffer salts, detergents and fragment contaminants).
  • interferring contaminants e.g., buffer salts, detergents and fragment contaminants.
  • Oligopeptides containing epitopes reactive with bactericidal antibodies against N. meningitidis can be produced by digestion of the class I OMP, CB-1 or CB-2 fragments with proteinases such as endoLys-C, endoArg-C, endoGlu-C and s taphylococcins V8-prote ⁇ ase.
  • the digested fragments can be purified by, for example, high performance liquid chromatograghic (HPLC) techniques.
  • Oligopeptides of this invention can be synthesized by standard solid peptide synthesis (Barany, G. and Merrifield, R.B., The Peptides 2:1-284,
  • synthetic peptides can be prepared by pepscan synthesis (Geysen, H.M. et al., J. Immunol. Methods 03:259 (1987); Proc. Natl. Acad. Sci. USA 81:3998 (1984)), Cambridge Research Biochemicals, Cambridge, U.K. or by standard liquid phase peptide synthesis.
  • pepscan synthesis Gaysen, H.M. et al., J. Immunol. Methods 03:259 (1987); Proc. Natl. Acad. Sci. USA 81:3998 (1984)
  • Cambridge Research Biochemicals Cambridge, U.K.
  • the deletion or substitution of amino acids in other ways which do not substantially detract from the immunological properties of the oligopeptide.
  • the Class I OMP, fragments and oligopeptides which exhibit epitopes of the Class I OMP can be produced by recombinant DNA techniques. In general, these entail obtaining DNA sequences which encode the desired OMP, [Barlow et al., (1989) Mol. Micro., 3:131) fragment or oligopeptide sequences and introducing into an appropriate vector/host expression system one or more similar or different DNA sequences of Class I OMP's where it is expressed.
  • the DNA can consist of the gene encoding the Class I OMP or any segment of the gene which encodes a functional epitope of the OMP.
  • the DNA can be fused to DNA encoding other antigens of N.
  • meningitidis such as other outer membrane proteins either of the same or different class
  • antigens of other bacteria, viruses, parasites or fungi to create genetically fused (sharing a common peptide backbone), multivalent antigens.
  • Class I OMP fragments can be fused to another class 1 outer membrane protein of a different subtype (or fragments or epitopes thereof) of N. meningitidis to yield fusion proteins comprising multiple class 1 outer membrane protein subtype determinants.
  • Genetic engineering techniques can also be used to characterize, modify and/or adapt the encoded peptides or proteins. For example, site directed mutagenesis to modify an OMP fragment in regions outside the protective domains, for example, to increase the solubility of the subfragment to allow easier purification.
  • DNA can also be manipulated to effect superproduction of OMP fragments or combinations thereof in various organisms.
  • DNA encoding a Class I OMP, fragments or oligopeptides can be synthesized or isolated and sequenced as described by Barlow, A.K. et al. Infect.
  • Class I OMP genes can be amplified from bacterial DNA by the methods of
  • a variety of host-vector systems can be used to express the oligopeptides of this invention.
  • Host-vector systems include but are not limited to the following: bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus).
  • the expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used.
  • RNA polymerase normally binds to the promoter and initiates transcription of a gene or a group of linked genes and regulatory elements (called an operon) . Promoters vary in their
  • promoters i.e., their ability to promote transcription. It is desirable to use strong promoters in order to obtain a high level of transcription and, hence, a high level of DNA expression.
  • any one of a number of suitable promoters can be used.
  • promoters such as the lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, and P R or P L promoters of coliphage lambda and others including but not limited to lacUV5, ompF, bla, 1pp and the like, may be used to -direct high levels of transcription of adjacent DNA segments.
  • a hybrid trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted DNA.
  • Bacterial host cells and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced.
  • the addition of specific inducers is necessary for efficient transcription of the inserted DNA; for example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside).
  • IPTG isopropylthio-beta-D-galactoside
  • trp is under different controls.
  • the trp operon is induced when tryptophan is absent in the growth media; and the P L promoter of lambda can be induced by an increase in temperature in host cells containing a temperature sensitive lambda repressor, e.g., cI857.
  • promoter--directed transcription may be inhibited in uninduced cells.
  • expression of the recombinant peptide or protein can be controlled. This is important if the expression product of the DNA is lethal or detrimental to the host cells.
  • transformants may be cultured under conditions such that the promoter is not induced; then, when the cells reach a suitable density in the growth medium, the promoter can be induced for production of the protein.
  • tac trp-lac promoter/operator system
  • trp-lac promoter/operator system Russell and Bennett, 1982, Gene 20:2312-243; DeBoer, European Patent Application, 67, 540 filed May 18, 1982.
  • This hybrid promoter is constructed by combining the -35 b.p. (-35 region) of the trp promoter and the -10 b.p. (-10 region or Pribnow box) of the lac promoter (the sequences of DNA which are the RNA polymerase binding site).
  • tac is also controlled by the lac repressor.
  • enhancer sequences When cloning in a eukaryotic host cell, enhancer sequences (e.g., the 72 bp tandem repeat of SV40 DNA or the retroviral long terminal repeats or LTRs, etc.) may be inserted to increase transcriptional efficiency. Enhancer sequences are a set of eucaryotic DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene.
  • enhancer sequences Unlike the classic promoter elements (e.g., the polymerase binding site and the Goldberg-Hogness "TATA" box) which must be located immediately 5' to the gene, enhancer sequences have a remarkable ability to function upstream from, within, or downstream from eucaryotic genes; therefore, the position of the enhancer sequence with respect to the inserted DNA is less critical.
  • classic promoter elements e.g., the polymerase binding site and the Goldberg-Hogness "TATA" box
  • Specific initiation signals are also required for efficient gene transcription and translation in procaryotic cells. These transcription and translation initiation signals may vary in "strength” as measured by the quantitiy of gene specific messenger RNA and protein synthesized, respectively.
  • the DNA expression vector, which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in E. coli
  • SD Shine-Dalgarno
  • ATG initiation codon
  • any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include but are not limited to the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.
  • any of the methods described for the insertion of DNA into an expression vector can be used to ligate a promoter and other genetic control elements into specific sites within the vector.
  • N. meningitidis sequences for expression can be ligated into an expression vector at a specific site in relation to the vector promoter and control elements so that when the recombinant DNA molecule is introduced into a host cell the foreign genetic sequence can be expressed (i.e., transcribed and translated) by the host cell.
  • the recombinant DNA vector can be introduced into appropriate host cells (bacteria, virus, yeast, mammalian cells or the like) by transformation, transduction or transfection (depending upon the vector/host cell system).
  • Host cells containing the vector are selected based upon the expression of one or more appropriate gene markers normally present in the vector, such as ampicillin resistance or tetracycline resistance in pBR322, or thymidine kinase activity in eucaryotic host systems.
  • Expression vectors may be derived from cloning vectors, which usually contain a marker function.
  • Such cloning vectors may include, but are not limited to the following: SV40 and adenovirus, vaccinia virus vectors, insect viruses such as baculoviruses, yeast vector, bacteriphage vectors such as lambda gt-WES- l amb da B , Charon 28 , Charon 4A, lambda gt-1-lambda BC, lambda gt-1-lambda B, M13mp7, M13mp8, M13mp9, or plasmid DNA vectors such as pBR322, pAC105, pVA51, pACYC177, pKH47, pACYC184, pUBH110, pMB9 , pBR325, Col E1, pSC101, pBR313, pML21, RSF2124, pCR1, RP4, pBR328 and the like.
  • SV40 and adenovirus vaccinia virus vectors
  • insect viruses
  • Expression vectors containing the DNA inserts can be identified by three general approaches: (1) DNA-DNA hybridization using probes comprising sequences that are homologous to the inserted gene; (2) presence or absence of "marker" gene functions (e . g. , resistance to antibiotics, transformation phenotype, thymidine kinase activity, etc.); and (3) expression of inserted sequences based on the physical immunological or functional properties of the gene product.
  • the gene product can be analyzed as follows. Immunological analysis is especially important because the ultimate goal is to use the gene products in vaccine formulations and/or as antigens in diagnostic immunoassays.
  • the expressed peptide or protein should be immunoreactive with bactericidal antibodies against N. meningitidis.
  • the purified preparation however produced should be substantially free of host toxins which might be harmful to humans.
  • the purified peptide or protein when expressed in gram negative bacterial host cells such as E. coli or Salmonella, should be substantially free of endotoxin contamination.
  • Class I OMP, fragments and oligopeptides of this invention can be formulated as univalent and multivalent vaccines. These materials can be used as produced or isolated by the methods described above. They can be mixed, conjugated or fused with other antigens, including B or T cell epitopes of other antigens. In addition, they can be conjugated to a carrier protein as described below for oligopeptides.
  • a haptenic oligopeptide i.e., a peptide which reacts with cognate antibodies, but cannot itself elicit an immune response
  • it can be conjugated to an immunogenic carrier molecule.
  • Conjugation to an immunogenic carrier can render the oligopeptide immunogenic.
  • the conjugation can be performed by standard procedures.
  • Preferred carrier proteins for the haptenic oligopeptides are toxins, toxoids or any mutant crossreactive material (CRM) of the toxin from tetanus, diphtheria, pertussis, Pseudomonas, E. coli, Staphylcoccus, and
  • a particularly preferred carrier is CRM 197 of diphtheria toxin, derived from P.
  • diphtheriae strain C7 ( ⁇ 197) which produces CRM 197 protein.
  • This strain has ATCC accession no. 53281.
  • a fragment or epitope of the carrier protein or other immunogenic protein can be used.
  • the hapten can be coupled to a T cell epitope of a bacterial toxin, toxoid or CRM. See U.S. Patent Application Serial No. 150,688, filed February 1, 1988, entitled "Synthetic Peptides
  • T-Cell Epitope As a Carrier Molecule.
  • Other carriers include viral particles composed of Rotavirus VP6, Hepatitis B surface antigen or parvovirus VP1 and VP2.
  • the peptides or proteins of this invention can be administered as multivalent subunit vaccines in combination with antigens of N. meningitidis or antigens of other organisms. Some of the other organisms include the pathogenic bacteria H.
  • influenzae N. meningitidis, B. catarrhalis, N. gonorrheae, E. coli, S. pneumoniae, etc.
  • they may be administered in conjunction with oligo- or polysaccharide capsular components of N. meningitidis.
  • the capsular components can be derived from any of the serological groups,
  • Class 1 outer membrane proteins of different subtypes can be used. These may be used in combination to evoke bactericidal antibodies against N. meningitis.
  • a fragment derived from class 1 outer membrane protein of the P1.7.16 subtype can be used together with outer membrane proteins or fragments of outer membrane proteins of other subtypes, such as P1.1, P1.1,16; P1.2; P1.6; P1.9; P1.15; P1.16; or P1.4 (Abdillahi, H. et al. 1988 Micro. Pathog. 4:27) or with meningococcal polysacchar ides in mixtures or as chemical conjugates.
  • conjugates can be formed by standard techniques for coupling proteinaceous materials or techniques for coupling saccharide polymers to proteins. Fusions can be expressed from fused gene constructs prepared by recombinant DNA techniques as described.
  • Class I OMP, fragment or any oligopeptides derived therefrom can be used in conjunction with antigens (e.g., polymer capsules or saccharide units, envelope or surface proteins) of other pathogenic organisms (e.g. bacteria (encapsulated or nonencapsulated), viruses, fungi and parasites). Additional examples of other organisms include respiratory syncytial virus, rotavirus, malaria parasites, and Cryptococcus neoformans.
  • antigens e.g., polymer capsules or saccharide units, envelope or surface proteins
  • pathogenic organisms e.g. bacteria (encapsulated or nonencapsulated)
  • viruses fungi and parasites
  • Additional examples of other organisms include respiratory syncytial virus, rotavirus, malaria parasites, and Cryptococcus neoformans.
  • Suitable adjuvants include, but are not limited to: surface active substances, e.g., hexadecylamine, octadecylamine, octadecyl amino acid esters, lysolecithin, dimethyldioctadecylammonium bromide), methoxyhexadecylgyIcerol, and pluronic polyols; polyamines, e.g., pyran, dextransulfate, poly IC, carbopol; peptides, e.g., muramyl dipeptide and derivatives, dimethylglycine, tuftsin; oil emulsions; and mineral gels, e.g., aluminum hydroxide, aluminum phosphate, etc., lymphokines and immune stimulating complexes
  • surface active substances e.g., hexadecylamine, octadecylamine, octadecyl amino
  • the immunogen may also be incorporated into liposomes, microspheres, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation.
  • the vaccines can be administered to a human or animal in a variety of ways. These include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. Live vaccines
  • the peptide and proteins of this invention can be administered as live vaccines.
  • recombinant microorganisms are prepared that express the peptides or proteins.
  • the vaccine recipient is inoculated with the recombinant microorganism which multiplies in the recipient, expresses the Class I OMP, fragment or oligopeptide thereof and evokes a Immune response to N. meningitidis.
  • Live vaccine vectors include: adenovirus, cytomegalovirus and preferably, pox viruses such as vaccinia (Paoletti and Panicali, U.S. Patent No. 4,603,112) and attenuated Salmonella strains (Stocker, U.S. Patent No. 4,550,081 and Curtiss et al., Vaccine 6: 155-160 (1988)).
  • class I OMP epitopes can be incorporated into the flagella of attenuated
  • Live vaccines are particularly advantageous because they lead to a prolonged stimulus which can confer substantially long-lasting immunity.
  • the live vaccine itself may be used in a preventative vaccine against N.meningitidis.
  • Multivalent live vaccines can be prepared from a single or a few recombinant microorganisms that express different epitopes of N. meningitidis (e.g., other outer membrane proteins from other subtypes or epitopes thereof).
  • epitopes of other pathogenic microorganisms can be incorporated into the vaccine.
  • a vaccinia virus can be engineered to contain coding sequences for other epitopes in addition to those of N. meningitidis.
  • Such a recombinant virus itself can be used as the immunogen in a mulivalent vaccine.
  • a mixture of vaccinia or other viruses, each expressing a different gene encoding for different epitopes of outer membrane proteins of N. meningitidis and/or epitopes of other disease causing organisms can be formulated as a multivalent vaccine.
  • An inactivated virus vaccine may be prepared.
  • Inactivated vaccines are "killed", i.e., infectivity has been destroyed, usually by chemical treatment (e.g., formaldehyde treatment). Ideally, the infectivity of the virus is destroyed without affecting the proteins which carry the immunogenicity of the virus.
  • chemical treatment e.g., formaldehyde treatment
  • large quanitites of the recombinant virus expressing the desired epitopes are grown in culture to provide the necessary quantity of relevant antigens.
  • a mixture of inactivated viruses express different epitopes may be used for the formulation of "multivalent” vaccines. In certain instances, these "multivalent" inactivated vaccines may be preferable to live vaccine formulation because of potential difficulties arising from mutual interference of live viruses administered together.
  • the inactivated virus or mixture of viruses may be formulated in a suitable adjuvant in order to enhance the immunological response to the antigens.
  • suitable adjuvants include: surface active substances, e.g., hexadecylamine, octadecyl amino acid esters, octadecylamine, lysolecithin, dimethyl-dioctadecylammonium bromide, N, N-dicoctadecyl-N', N'bis (2-hydroxyethyl-propane diamine), methoxyhexadecylglycerol, and pluronic polyols;
  • polyamines e.g., pyran, dextransulfate, poly IC, carbopol
  • peptides e.g., muramyl dipeptide and derivatives thereof, dimethylglycine, tuftsin
  • oil emulsions e.g., mineral gels, e.g., aluminum hydroxide, aluminum phopshate, and lymphokines.
  • OMP's and Their Biological Activity Type specific monoclonal antibodies were prepared against various meningococci Class 1 outer-membrane proteins. These monoclonal antibodies recognize the following subtypes: P1,1;
  • the monoclonal antibodies are available as "Monoclonal Kit Serotyping Meningococci" from the RIVM, Bilthoven, The Netherlands. All these monoclonal antibodies react with the SDS (sodium dodecyl sulphate) denatured protein when tested by Western blotting. It also emerged that a number of these monoclonal antibodies reacted with a 25Kd CNBr fragment of the 42Kd Class 1 outer-membrane protein (see below).
  • SDS sodium dodecyl sulphate
  • Class 1 outer-membrane protein epitopes are mainly of linear type and can therefore be copied with synthetic peptides.
  • the epidemiological results of tests carried out by the Applicants show that the described monoclonal antibodies can subtype most of the group A,B,C meningococci which suggests a limited heterogenity.
  • Each Class 1 outer membrane protein also appears to contain two individual type specific epitopes (Abdillahi and Poolman, Microb. Pathogen, 1988, 4: pages 27-32; idem FEMS Microbiol. Immunol. 47: pages 139-144).
  • the purified Class 1 outer-membrane protein (see below), subtype P1, 7.16, originating from the culture of the Class 2/3 free mutant (HIII5) appeared to induce a bactericidal antibody response of 1:64 serum dilution in a dose of 2.5 ⁇ g in mice.
  • the monoclonal antibodies against meningococci Class 1 outer-membrane proteins, Class 2/3 outer-membrane proteins and lipopolysacchar ides were compared as to bacteridical effect.
  • the bacterial response was determined as per Poolman, J.T. (1985), in Schoolnick, G.J. et al. Eds. 'The Pathogenic Neisseriae' ASM Publications, Washington, D.C., page 562. TABLE 1
  • Test strain Bactericidal activity of antibody pool (titre) strain (Gp:serotype: C1 2/3 pool C1 1 pool LPS pool subtype:LPS type)
  • H355 (B:15:P1.15:L1.8) 1000 8000 1000
  • bactericidal activity of these monoclonal antibodies appears to correlate well with the in vivo protective activity as measured in the rat meningitis model of Saukkonen et al., 1987, Microbial Pathogen 3: 261.
  • EXAMPLE 1A Construction_of_meningococcal strains carrying multiple Class 1 genes
  • An essential feature of the method is the presence of the donor gene on a circular plasmid DNA molecule that is not able to replicate in N . meningitidis, since the use of linearized DNA yielded no transformants at all.
  • the different Class 5 genes can be clones and used separately. These recombinant strains can be used to prepare mixtures of different purified Class I OMPs.
  • EXAMPLE 1B Purification of isolated OMV's from bacteriological culture
  • the purification is carried out according to Beuvery et al. (1983) loc. cit.
  • This culture can be done with the desired wild type strains, mutant meningococci strains without Class 2/3 outer-membrane proteins and/or homologeous and heterologeous recombinant microorganisms which express one or more of the desired meningococci Class 1 outer-membrane protein and/or epitopes by overproducing vectors either through or not through existing open reading frames and/or manipulated reading frames so that fusion proteins or proteins with exchanged epitopes can be prepared.
  • the semisynthetic medium had the following composition: L-glutamic acid 1.3 g/l, L-cysteine.HCl 0.02 g/l, Na 2 HPO 4 .2H 2 O 10 g/l, KCl 0.09 g/l, NaCl 6 g/l, NH 4 Cl 1.25 g/l, MgSO 4 .7H 2 O 0.6 g/l, glucose 5 g/l, Fe(NO 3 ) 3 100 ⁇ M, yeast dialysate.
  • the pH and PO 2 were monitored and automatically regulated to a pH of 7.0-7.2 and an air saturation of 10%.
  • the cells were grown to early stationary phase harvested by means of centrifuging and washing with sterile 0.1 M NaCl and stored at -20°C or freeze-dried.
  • This culture can be done with the desired wild type strains, mutant meningococci strains without Class 2/3 outer-membrane proteins and/or homologeous and heterologeous recombinant microorganisms which express one or more of the desired meningococci Class 1 outer-membrane protein and/or epitopes by overproducing vectors either through or not through existing open reading frames and/or manipulated reading frames so that fusion proteins or proteins with exchanged epitopes can be prepared.
  • H44/76 (B: 15 :P1, 7.16) (Holten E., Norway, deposited as CBS 635-89); 1JT7 (B:4:P1,7) (Etienne J., France); M1080 (B:1:P1,1.7) (Frasch C, USA); Swiss4
  • the semisynthetic medium had the following composition: L-glutamic acid 1.3 g/l, L-cysteine.HCl 0.02 g/l, Na 2 HPO 4 .2H 2 O 10 g/l, KCl 0.09 g/l, NaCl 6 g/l, NH 4 Cl 1.25 g/l, MgSO 4 .7H 2 O 0.6 g/l, glucose 5 g/l, Fe(NO 3 ) 3 100 ⁇ M, yeast dialysate.
  • the pH and PO 2 were monitored and automatically regulated to a pH of 7.0-7.2 and an air saturation of 10%.
  • the cells were grown to early stationary phase harvested by means of centrifuging and washing with sterile 0.1 M NaCl and stored at -20oC or freeze-dried.
  • the bacterial mass was for example extracted with the aid of 0.5 M CaCl 2 , 1% (w/v) Zwittergent 3-14 (Zw 3-14) and 0.14 M NaCl, pH 4.0, using 100 ml per gram of freeze-dried bacterial mass. The suspension was stirred for 1 hour at room
  • Cyanogen bromide was used to prepare fragments of meningococci Class 1 outer-membrane proteins.
  • the purified Class 1 or mixtures of Class 1 or 3 outer-membrane proteins were taken up in 70% (v/v) formic acid and treated with a 10-fold excess of CNBr for 16 hours at room temperature.
  • the CNBr and the formic acid were removed by means of evaporation and replaced by 0.2 M Tris.HCl, 6 M urea solution, pH 7.2.
  • the supernatant was prepurified by means of gel filtration over Sepharyl S-200 and subsequently purified with the aid of TSK-2000 gel filtration via HPLC. Beuvery et al., (1986) supra.
  • meningococcal CB2 fragment was subjected to
  • EndoArg-C (1mg/ml in distilled water) or 0.22 nMoles of EndoGlu-C or V-8 (1 mg/ml in distilled water) for 14-18 hours.
  • the resulting digested fragments were separated by reverse phase HPLC using a Vydac-C4 column and a trifluoroacetic acid-acetonitrile gradient.
  • the main peak eluted from the EndoArg-C digestion had an apparent molecular weight of 7-9 Kdal while the main peak observed following
  • EndoGlu-C or V-8 had an apparent molecular weight of 4-6 Kdals.
  • the isolated peaks were subsequently shown by Western blot to react to a pool of
  • V8 7-9Kd fragment FSGFSGSVQFVP1QNSKSAYTPAYYTKDTN ...
  • Arg-C 4-6Kd fragment PVSVRYDSPEFSGFSGSVQFVPIQNSKSAYTPAYYTK...
  • Amino acid sequences of Class I OMP were deduced from the nucleotide sequence of the structural genes of four meningococci Class 1 OMP's with various subtypes. Comparison with four amino acid sequences enabled a prediction of the composition and the location of these epitopes. Further, the P1, 7 and P1, 16 epitopes were confirmed with the aid of peptide synthesis and the demonstration of binding of the . respective monoclonal antibodies.
  • the primers used had the following sequences:
  • PR1 (41 bases with universal primer extension)
  • TGT AAA ACG ACG GCC AGT GGC GAA TTC GGT ACG CTG CGC GCC
  • PR4 (40 bases with universal primer extension) TGT AAA ACG ACG GCC AGT GCA GAT TGG CAG TCA GAT TGC A
  • TGT AAA ACG ACG GCC AGT GGG ATC GGT ACC TTT GGC TTG A
  • TGT AAA ACG ACG GCC AGT AAC TGA TTC GCA ACG CGA CCG G
  • VR1 and VR2 epitopes are designated as the VR1 and VR2 epitopes.
  • sequence YYTKNTNNNL is present, the change D to N at residue 180 does have some effect on reducing antibody binding.
  • the sequence HYTRQNNTDVF in P1.15 in the same relative position in the protein as the P1.16 epitope and is responsible for binding to the antl-P1.15 monoclonal antibody.
  • AQAANGGASG shows some binding and peptides 1-3 amino acids downstream show far greater binding to the P1.7 monoclonal antibody.
  • QPQVTNGVQGN and PPSKSQP in the P1.16 and P1.15 proteins also represent epitopes.
  • peptides and their surface region location which were conjugated to TT are as follows:
  • N-succinimidyl bromoacetate (4.7 mg, 10 ⁇ mol) in DMF (100 ⁇ l) was mixed with a solution of tetanus toxoid (TT) (20 mg) in 0.1 M. sodium phosphate buffer pH. 7.8 (3.5 ml). After 1h, 1.8 ml of the reaction mixture was subjected to gel filtration using a Sephadex PD-10 column (Pharmacia) equilibrated in 0.1 M sodium phosphate, containing 5mm EDTA (PE buffer) ph 6.1. The bromoacetylated tetanus toxoid was eluted with the same buffer and collected in 3.5 ml.
  • TT tetanus toxoid
  • OMP Outer membrane proteim
  • Class I OMP Purified Class I OMP
  • BC Bactericidal activity
  • meningitidis loop 5 appears to represent at least
  • EXAMPLE 7 Construction of recombinant flagellins expressing meningococcal epitopes
  • oligonucleotides were designed based on primary protein sequence data and epitope mapping data. Two oligonucleotides based on VR1 or VR2 epitopes of outer membrane P1.7.16 were designed so that they could be cloned in single or multiple copies into a cloning region within the gene for S. muenchen flagellin. Translation termination signals were included on the non-coding strand of the oligonucleotide to facilitate screening by expression of the cloned inserts.
  • the plasmid vector pPX1650 containing the entire coding region and promoter regions for the structural gene for flagellin H1-d of Salmonella meunchen was modified to contain several unique cloning sites suitable for the insertion of either oligonucleotides or gene fragments in each of the three reading frames of the flagellin gene ( Figure 6).
  • pPX1650 was digested with EcoRV, which cleaves pPX1650 twice, 48 base pairs apart, and religated to yield a plasmid, pPX1651, which has a unique EcoRV cloning site and which results in a 16 amino acid deletion in the flagellin protein.
  • pPX1651 was identified by screening E. coli recombinants on Western blots probed with polyclonal antibody directed against H1-d flagellin.
  • pPX1651 was identified amongst several candidates having
  • pPX1651 was restricted with BamHl and religated after filling out the overhanging ends with Klenow enzyme to remove the unique BamHl restriction enzyme site in the polylinker region of the vector.
  • Klenow enzyme to remove the unique BamHl restriction enzyme site in the polylinker region of the vector.
  • the resulting vector was digested with EcoRV and the following oligonucleotide linker was inserted:
  • Plasmid pPX1647 ( Figure 7) was digested with BamH and either oligonucleotides for VR1 or VR2 were cloned into E. coli cells. Screening for desired recombinants was accomplished by digesting plasmid minilysate DNA with appropriate diagnostic restriction enzymes and screening for expression by probing hybrid flagella for decreased mobility on SDS-PAGE gels with specific flagellar antiserum (H1-d). A number of the resultant clones showed decreased mobility on SDS-PAGE, indicating proper insertion of one or more of the oligonucleotides for VR1 or VR2. Several of each were retained for analysis by DNA sequencing.
  • Clone CB1-2 results from tandem insertion of two copies of the VR1 oligonucleotide and clone CB1-4 results from insertion of four oligonucleotides.
  • CB2 P contained a single insert of the VR2 oligonucleotide and CB2 W showed the expected trimeric insert,
  • CB2 P clone contained, a single base pair change which resulted in a change from Leu to Phe in the expressed VR2 fusion protein and was not retained for further study.
  • the recombinant flagellin clones in E. coli were probed with monoclonal antibodies
  • the CB2 P clone fails to react with either VR2 antibody, probably due to the Leu to Phe change.
  • Each of these clones was transformed into an aroA S. dublin strain (SL5927), having a Tn10 insertion in the H1-d locus, to examine the
  • Hybrid flagellin containing both VR1 and VR2 epitopes were created by cleaving either CB1-2, CB1-4, or CB2 W with BamH1 and cloning the heterologous epitope.
  • Clones CB12-7 and CB12-10 result from the in-frame insertion of a single copy of the VR2 oligonucleotide behind either 2 or 4 VR1 tandem inserts, respectively; clone CB21-F arose from the insertion of one copy of the VR1 epitope behind 3 tandem copies of VR2.
  • CB12-7 and CB12-10 are recognized only by VR1 monoclonal antibody and
  • CB21-F is recognized only by VR2 monoclonal. These results, taken together with DNA analysis revealing predicted sequences, indicate epitope density is too low in the combined hybrids.
  • CB12-10 was digested with BamH1 and VR2 encoding oligonucleotides were inserted.
  • Clone 12-10-6 contains two further tandem inserts of the VR2 epitope, resulting in a hybrid flagellin molecule in which four tandem copies of VR1 are followed by three copies of VR2.
  • Figure 3a and b three of the hybrid flagellin vaccine candidates have the expected molecular properties.
  • the flagellin (pCB1 x 4) containing 4 copies of VR1 reacts with anti-H1-d (anti-flagellin) and anti-VR1 monoclonal antibodies, but not with anti-VR2 monoclonal antibodies; the flagellin
  • a suitable vaccine candidate can be chosen from the above type constructions based on reactivity to monoclonal antibodies and function of flagella in non-motile Salmonella host strains.
  • a subunit flagellin vaccine may not need to retain all functional aspects of a parental flagellin, but should at least retain surface localization for purification purposes.
  • Several subunit flagellin meningococcal vaccine were chosen from the above described hybrid molecules based on reactivity to monoclonal antibodies and implied surface localization based on restoration of bacterial motility.
  • Three flagellin vaccine candidates contained either 4 tandem inserts of VR1, 3 tandem inserts of VR2, or 4 VR1 inserts followed by 3 VR2 inserts. Because flagellin is a major protein of Salmonella, it is possible to easily purify sufficient material for vaccination studies using techniques established for flagella purification (Logan et al . , J. Bacteriol. 169: 5072-5077, 1987).
  • the three hybrid flagellin vaccine candidates and a wild type were inoculated into four-liter baffled Fernbach flasks containing 1 liter of LB broth. Bacterial cultures were incubated at 37oC with shaking (200 rpm) for 22-24 hr. Under these conditions of culturing, the bulk of the flagella were sloughed from the bacterial cell surface and were localized in the supernatant culture medium. To obtain suitable material, flagella were isolated from 6-8 liters of culture medium.
  • flagellar filaments were harvested from bacterial culture supernatants by the following procedure: Ammonium sulfate was added to culture supernatant so that final solution was 50% saturated; the solution was stirred gently at 4°C for several hours and the precipitated material was collected by centrifugation in a GSA rotor at 5000 rpm for 30 minutes. The collected ammonium-sulfate precipitated material was reconstituted in PBS and dialyzed against PBS at 4oC for 12-15 hrs. The dialyzed material was subjected to high speed centrifugation at 100,000 x g for 1 hour in an SW-27 rotor to pellet the flagellar filaments. The pelleted material, which consisted primarily of flagellin, was subjected to further purification by the following method.
  • the dialyz e d f rac t i ons were then l o ade d onto a TSK SP PW cation exchange HPLC column (75mm x 300mm).
  • the column was eluted with a mobile phase consisting of lOmM Acetate (pH-4.0) containing 6M urea.
  • the flagellin construct was collected at approximately 24 min. which corresponds to about 200mM NaCl.
  • the fraction was dialyzed against PBS and purity determined on the material was established by Western blots using anti-flagellin antibody. A representative HPLC analysis and SDS-PAGE are shown in figures 8 and 9 respectively.
  • Group C meningoccal capsular polysaccharide (GCM CPS : lot # 86 NM 01) was prepared essentially according to Bundle et al. Bundel et al., J. Biol . Chem. 249: 4797-801, 1974).
  • Neisseria mengitidis strain C11 was obtained from the Walter Reed Army Institute (Washington, DC). The strain was precultured twice on sheep blood agar plates, then used for the inoculation of a liquid seed culture medium Neisseria chemically defined medium, NCDM) Kenney et. al., Bull. W.H.O. 37 469-73, 1967). Finally, 40 1 of liquid medium (NCDM) in a fermentor was inoculated with the liquid preculture. The purity of the strain was checked at each stage.
  • NCDM liquid seed culture medium
  • the CPS was then dissolved in sodium acetate buffer (1.10 dilution of a saturated solution, pH 7.0) and extracted four times wiht hot phenol (Westphal et al., Z. Naturforach. 7b: 148-55, 1952). After dialysis of the combined aqueous phases against 0.1 M CaCl 2 , followed by centrifugation (3-5 h, 100,000 g), a final ethanol precipitation was performed on the clear supernatant, and the
  • GCM CPS Group C meningococcal capsular polysaccharide
  • GCM OS activated oligosaccharides
  • GPC low pressure gel permeation
  • a solution was then prepared in water and subsequently frozen for temporary storage.
  • GCM OS and flagellin pCB12-10-6 were mixed in aqueous neutral buffer and the conjugation was initiated by addition of sodium cyanoborohydride (NaBH 3 CN)
  • GCM OS (2 mg; final concentration: 2.6 mg/ml) and flagellin p.CB12-10-6 (2.3 mg; final concentration: 3 mg/ml) were mixed in a polypropylene tube in 0.4 M sodium phosphate buffer (pH 7.0), and
  • NaBH 3 CN was added (12 ⁇ moles) to initiate the conjugation (Anderson, U.S. Patent 4,762,713, 1988; U.S. Patent 4,673,574; U.S. Patent 4,761,283).
  • the reaction mixture was left one day at RT, then 4 days at 35°C, without agitation.
  • the reaction was monitored by HPGPC (UV at 280 nm) at different stages, and finally stopped by dialysis/concentration on microconcentrators.
  • the final preparation was analyzed for NANA (Barry et al . , J. Gen. Microbiol. 29:335-353, 1962) (0.09 mg at 0.12 mg/ml) and protein (Lowry et al . , J. Biol. Chem. 193:265-275,
  • Peptides designated as M20 and M21 were produced on an ABI model-pep tide synthesizer by solid phase synthesis using the tBoc chemistry were coupled to CRM 197 (prepared as described by Andersen, U.S. Patent No. 4,762,713) using a bifunctional crosslinking agent, sulfosuccinimidyl (4-iodoacetyl) amino benzoate (Sulfo SIAB; purchased from Pierce) following the modification of a published procedure (Weltman, J.K. et al., (1983) Bio Techniques 1, 148-152). Briefly CRM 197 was activated by sulfo SIAB resulting in the formation of an amide bond between SIAB and amino groups of CRM 197 .
  • peptide (M20 or M21) containing linking spacer (represented in underlined letters) with carboxy terminal cysteine residue was mixed with activated CRM and incubated at room temperature for 2-4 hours. Following the reaction, the conjugated material was dialyzed extensively against PBS at 4 C.
  • FIG. 10a and 10b show the western blot analysis of M20 and M21 CRM 197 conjugates, against a pool of VR1 and VR2 specific monoclonals (Adam I, G2-D12-8 (P1.7),
  • BSA conjugates were prepared by using a different bifunctional crosslinking agent, N-Succinimidyl Bromoacetate as described by Bernatowicz and Matsueda (Anal. Biochem. 155, 95-102 (1986)). Covalent coupling of peptide to the protein was confirmed by western blotting of electrophoresed samples as described for CRM 197 conjugates.
  • mice were immunized with 50 ⁇ g of native CRM197 emulsified in CFA. Seven days later, lymph nodes were removed, cultured in RPMI and challenged with various concentrations of proteins (0.05-100.0 ⁇ g/ml) and peptides. After 3 days incubation, cultures were pulsed with [ 3 H]-thymidine for 16 hours and then harvested for counting
  • Recombinant flagellin expressing the meningococcal VR1 and/or VR2 epitopes were prepared and purified as described in Examples 7 , 8 and 9.
  • synthetic peptides representing the meningococcal epitopes VR1 and VR2 were synthesized, covalently coupled to the carrier molecule CRM 197 and purified as in Example 12.
  • Vaccines were formulated with each of these materials at protein concentrations of 10 or 100 ⁇ g/ml for each of the components.
  • the vaccine compositions also included aluminum phosphate at 1 mg/ml or except as noted were compounded with Freund's complete adjuvant or without supplemental material.
  • Webster mice were immunized intramuscularly at weeks 0 and 2 with 1 or 10 ⁇ g protein/dose.
  • Sera were collected at two week intervals, pooled for assay, and screened for antibody activity by ELISA to outer membrane complex (OMC), purified OMP (P1.16), VR1 peptide coupled to Bovine serum albumin (M21-BSA), VR2 peptide coupled to BSA (M20-BSA), wildtype flagellin, and to CRM 197 .
  • OMP outer membrane complex
  • M21-BSA Bovine serum albumin
  • M20-BSA VR2 peptide coupled to BSA
  • wildtype flagellin and to CRM 197 .
  • the results of the ELISA performed on sera obtained at 6 weeks are shown in Table 4.
  • mice were immunized with 100 ⁇ g
  • total protein (total protein)/dose subcutaneously on week 0 and 4
  • the recombinant flagellins containing either a VR1, VR2 or a cassette of both VR1 and VR2 were effective in eliciting an antibody response which was cross-reactive to the purified P1.16 and to a lesser extent to OMC .
  • Sera from animals immunized with 10 ⁇ g of either pCB1-4 or pCB2-w induced antibodies which bound to their respective peptide--BSA conjugates as well as cross reacted with the P1.16 and OMC. Similar results were obtained with the constructed pCB12-10-6 which contains both meningococcal epitopes.
  • each construction induced significant anti-flagellin titers as well.
  • the control wildtype flagellin only induced an antibody response to flagellin itself. Sera collected prior to immunization showed no pre-existing response to the materials being evaluated.
  • the data also demonstrates the benefits of formulating the recombinant flagellins with alum or other adjuvants such as CFA.
  • the construction pCB12-10-6 was formulated with and without the addition of aluminum phosphate. As shown in table 2, pCB12-10-6 alone was capable of inducing an antibody response which react to the peptide conjugates as well as to the purified P1.16 as well as to OMC. In comparison, the same construction when formulated with alum was able to elicit greater antibody response at an equivalent dose.
  • the recombinant flagellins pCB1-4 and pCB2-w were also formulated with CFA. Again, equivalent or higher antibody titers were observed in the presence of CFA.
  • New epitope-carrier conjugates can be made using standard techniques to enhance the immune response to the vaccine, for example, use of 1) larger epitopes, 2) peptides with multiple epitope repeats and/or 3) different carriers.
  • GCM CPS was depolymerized by acid hydrolysis and GCM OS obtained were subsequently activated via
  • GCM CPS (lot # 86 NM 01; 106 mg ; final concentration: 10 mg/ml was hydrolyzed in 0.1 N HCl at 50°C with agitation. Aliquots (25 ⁇ l) were withdrawn at regular intervals, the reaction stopped by addition of sodium hydroxide (NaOH) and analysis was performed by HPGPC as described. After 3 h 40 min., the reaction was stopped by addition of NaOH, and the GCM OS were desalted by GPC. Fractions were collected (1.2 ml) and analyzed as described before. Positive fractions were pooled and lyophilized.
  • NaOH sodium hydroxide
  • Desalted GCM OS (89 mg) were then stored at -20°C.
  • Activated OS were prepared by oxidation of GCM OS (11.8 mg; final concentration: 5mg/ml) with 2 mM NaIO 4 in 0.05 M sodium phosphate buffer (pH 6.2-6.5) at RT, in the dark, with agitation. The reaction was stopped after 30 min by addition of ethylene glycol. HPGPC analyzes showed no degradation of the molecular weight of the OS during activation.
  • GCM OS activated GCM OS (8.8 mg) were dissolved in water (10 mg/ml) and frozen at -20°C. Both GCM OS and HA solutions were analyzed by HPGPC (UV at 206 and 280 nm respectively) before being frozen, and prior to the conjugation. No degradation occurred during storage, as ascertained by the exact similarity of the elution profiles.
  • GCM OS (6 mg; final concentration: 2.5 mg/ml) and HA (12 mg; final concentration: 5mg/ml) were mixed in a polypropylene tube in 0.4 M sodium phosphate buffer (pH 7.0), and NaBH 3 CN was added (60 ⁇ moles) to initiate the conjugation (Anderson, U.S. Patent 4,762,713, 1988; U.S. Patent 4,673,574, 1987; U.S. Patent 4,761,283, 1988). The reaction mixture was left one day at RT , then 4 days 15 35°C, without agitation. The reaction was monitored by HPGPC (UV at 280 nm) at different stages, and finally stopped by dialysis/concentration on microconcentrators.
  • HPGPC UV at 280 nm
  • the final preparation was analyzed for NANA (Barry et al. , J. Gen. Microbiol. 29P335-51, 1962) (2.07 mg at 0.86 mg/ml) and protein (Lowry et al . , J. Biol . Chem. 193265-75, 1951) (9.51 mg at 3.96 mg/ml) content. It was then stored at 4°C in the presence of thimerosal (0.01%, w/v) to prevent bacterial growth.
  • the conjugate preparation was also checked by SDS-PAGE (silver nitrate stain) and Western blot analyzes. A diffuse band appeared on the gel which covered a significantly wider molecular weight range than the pure HA. Western blot analyzes showed that this band was reactive with the antiserum used (anti-GCM), proving covalency of the conjugate bonds.
  • a meningococcal oligosaccharide-recombinant flagellin vaccine was prepared as described above and formulated at 100 ⁇ g pro.tein/ml.
  • Vaccine compositions were also prepared which contained aluminum phosphate (1 mg/ml) or complete Freund's adjuvant in addition to the glycoconjugate.
  • the MenC-CB12-10-6 glycoconjugate was effective at eliciting an immune response which was reactive with both the oligosacchar ide and the meningococcal B OMP epitopes expressed in the recombinant
  • mice immunized with 1 ⁇ g of MenC-CB12-10-6 conjugate in complete Freund's adjuvant had detectable antibody to MenC-HSA, OMP and to both the CB1 and CB2 epitopes. Further, all of the MenC-CB12-10-6 preparations, regardless of adjuvant, elicited antibody response to MenC-HSA which were greater than the response observed
  • MenC-CRMl97 alum 10 4,905 ND ND ND ND ND
  • Aluminum phosphate was used as adjuvant at 1 mg/ml.
  • EXAMPLE 16 T-cell epitopes of Class I OMP and their identification
  • T-cell epitopes within a protein can be predicted as described by Margalit et al . , J .
  • PBL peripheral blood lymphocytes
  • peripheral blood was collected from HLA typed normal volunteers or from volunteers who were previously immunized with MPC-2 (Poolman, J.T. e t al ., Antonie van Leeuwenhoek, 53: 413 - 419 , 1987) which contained P1.16, 15, Class 4 OMP and Group C polysaccharide.
  • Lymphocytes were isolated from the peripheral blood by isolation on Ficoll-Hypaque (Pharmacia Fine Chemicals AB , Uppsala, Sweden) and cultured at 1 X 10 5 cells/well in supplemented RPMI 1640 (Gibco Laboratories, Paisly, Scotland) containing 10% heat-inactivated pooled human AB serum. Cultures were challenged with various concentrations of the predicted T cell epitopes
  • peptides As shown in Table 9, 10 of the 16 predicted peptides showed some capacity to stimulate T-cells. These include the peptides identified at 16-34, 47-59, 78-90, 103-121, 124-137, 151-158, 176-185, 223-245, 276-291 and 304-322. In some instance, peptides stimulated a response in both immunized as well as non-immune individuals. The response in the non-immune individuals may be attributed to a previous asymptomatic infection.
  • T and B cell epitopes either coincide or are found on contiguous sequences within the Class I OMP.
  • T cell lines and clones were established from individuals responding to various peptides. Briefly, T cell lines were obtained by culturing isolated lymphocytes in 24 well plates at
  • U/ml recombinant IL-2 (Boehringer).
  • 5 x 10 4 homologous, irradiated (3,000R) antigen presenting cells (APC) were also added to each well.
  • APC were obtained from HLA compatible donors. From the lines, T cell clones were isolated by limiting dilution at a frequency of 0.5
  • Clones were maintained by bi-weekly stimulation with antigen in the presence of
  • Clones were tested by lymphocyte proliferation assay essentially as described above except that clones were cultured at 1 x 10 4 cells/well in the presence of irradiated
  • the clones recognized a T cell epitope or epitopes common to the seven OMPs examined. Although the reactivity of these clones to the various peptides remains to be determined, the data, nevertheless, does indicate
  • a model was constructed using the principles recognized for the structure of several Escherichia coli outer membrane Proteins (Vogel, H. et al.
  • Class 1 protein (subtype P1.16) with those of the gonococcal P1A and P1B proteins (Carbonetti, N.H. et al. (1987) PNAS 84:9084; Carbonetti, N.H. et al. (1988) PNAS 85:6841; and Gotschlich, E.C. et al. (1987) PNAS 84:8135) reveals 34% identity.
  • the variable sequences form the surface-exposed parts, whereas the conserved regions are placed mostly in the outer membrane and periplasm.
  • transmembrane segments should preferentially be able to form amphipathic beta-stands of 9-12 residues, with at least one side consisting entirely of hydrophobic residues. These conditions are met in 12 of the 16 membrane-spanning segments.
  • Figure 11 shows the model for the folding of Calss 1 protein in the outer membrane. The sequence shown is for subtype P1.16. The top part of the figure shows the surface-exposed regions, whereas the central part indicates the presumed transmembrane segments, whose length is set at ten.
  • Amino acid are shown alternating where they can form an amphipathic beta-strand.
  • This model contains eight surface loops, whereby the first and the fourth loop contain the type-specific and protective variable region epitopes. These epitopes, as has been shown when formulated into a vaccine, can elicit a protective immune response. Loop 5 is constant and has been shown to elicit cross-reactive antibodies to other OMPs and is useful for vaccine formulation.
  • the one or two variable epitope regions of the individual proteins are located on so called surface loops of these membrane proteins.
  • Such porin outer-membrane proteins contain more than two surface loops. This implicates that there are surface loops which have near identical amino acid sequence in the different Class 1 outer-membrane proteins as well. This opens the way to use of common peptides of the Class 1 outer-membrane protein for vaccine
  • FIG. 11 This model contains eight surface loops, whereby the first and the fourth loop contain the type specific epitopes as shown on the basis of strain subtyping results.
  • the fifth surface loop represents the constant region described above.
  • the N. meningitidis strain H4476 (B : 15 : P1.7,16) was deposited on December 11, 1989 in the Centraal Bureau voor Schimmelculturen (CBS), Baarn, The

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class 1 I OMP can be used to immunize against meningococcal disease.

Description

MENINGOCOCCAL CLAS S 1 OUTER -MEMBRANE PROTEIN VACC INE Description
Background of the Invention
Bacterial meningitis is an inflammatory disease of the central nervous system caused by the growth of bacteria in and adjacent to the leptomeninges. Meningitis is an acute infectious disease which affects children and young adults and is caused by the Neisseria meningitidis, amongst other agents including other bacterial and viral pathogens.
Meningococci are subdivided into serological groups depending on the presence of either capsular or cell wall antigens. Currently recognized sero- groups include A, B, C, D, W-135, X, Y, Z, and 29E as segregated by seroagglutination. The polysaccharides responsible for the serogroup specificity of the group A, B, C, X, W-135 and Y have been purified.
The carrier rate for meningococci is much higher than the incidence of the disease. Some persons are temporary carriers, while others are chronic carriers, discharging meningococci either more or less continuously or in a sporadic fashion. The meningococcal carrier state is an immunizing process, and within two weeks of colonization, production of antibodies to meningococci can be identified. It appears that bactericidal antibodies are directed against both the capsular polysaccharide and other cell wall antigens. Studies have shown that meningococcal outer membranes have three to five major proteins, with the predominant 41,000Mr or 38,000Mr proteins carrying the serotype specific determinants. There is a considerable degree of interstrain heterogeneity in the profiles of the outer membrane proteins on sodium dodecyl sulfate-polyacrylamide electrophoretic gels (SDS-PAGE). As defined by peptide mapping studies, the proteins comprise five classes, designated 1 through 5, based upon common peptide structures. Bactericidal monoclonal antibodies have been produced against the 46,000 Mr Class 1 proteins which are shared to some extent among strains of different serotypes. (Frasch, C.E. et al., (1985) pg. 633, "New Developments in Meningococcal Vaccines", in G.K. Schoolnik et al . (ed.)
The Pathogenic Nisseriae, American Society for
Microbiology, Washington, D.C.).
The capsular polysaccharide of groups A, C, W-135 and Y meningococci have been used to develop vaccines against the organism. Although these vaccines have been effective in the short term, they do not induce immunological memory and subjects must be revaccinated within approximately 3 years to maintain their resistance. The group B polysaccharide is poorly immunogenie and successful vaccines have not been produced. A possible explanation for the low activity may be due to tolerance to the group B polysaccharide induced by crossreactive antigens found in human tissues such as the brain. Furthermore, studies show that most of the bactericidal antibodies in the convelescent sera of patients who have had group B meningococcal disease are directed against outer membrane proteins.
Vaccines for protecting against group B meningococcal disease have been developed in which non-covalent complexes of outer membrane proteins (OMP) and group B polysaccharide were administered.
Beuvery, et al. (1983) Infect. Immun. 40:369-380. However, the B polysaccharide is known to induce a transient IgM antibody response, which does not confer immunoprotection. Furthermore, there is great antigenic. diversity and variability in the meningococci outer membrane proteins from strain to strain. Additionally, lipopolysaccharides are present in the OMP and exhibit antigenic variability as well.
There is a need for safe and effective vaccines against meningococcal disease which provide immunity from infection, particularly in infants and the elderly.
Summary of the Invention
This invention pertains to isolated outer membrane vesicles (OMV's), to substantially purified Class 1 outer membrane protein (OMP) of Neisseriameningitidis, to fragments of the Class I OMP and to oligopeptides derived from the Class I OMP which contain continuous or discontinuous, immunogenic and protective B cell epitopes reactive with
bactericidal antibodies against N. meningitidis and to the use of isolated OMV's, the meningococcal Class I OMP, fragments or oligopeptides for
vaccination against N. meningitidis.
The isolated OMV's, meningococcal Class I OMP, fragments or oligopeptides derived therefrom can be used in univalent or multivalent subunit vaccines alone, in mixtures, or as chemical conjugates or genetic fusions. In preferred vaccines, epitopes from different epidemiologically relevant
meningococcal strains are used. In addition, isolated OMV's, the Class I OMP, fragments or oligopeptides can be used in conjunction (as
mixtures, fusion or conjugates) with other antigens of N. meningitidis. For example, they can be used in conjunction with capsular polymers or oligomers (or fragments thereof) of N. meningitidis or with Class I outer membrane proteins(or epitopes thereof) of different subtypes. In addition, they can be used with antigens of other infectious bacteria, viruses, fungi or parasites. Class I OMP T cell epitopes also are defined and these can be used in conjunction with other vaccine components to enhance the protective immune response to the vaccines.
This invention also pertains to the methods of producing isolated OMV's, the Class I OMP, fragments and oligopeptides and to various vaccine
formulations containing them. The isolated OMV's Class I OMP can be produced by mutant meningococcal strains which do not express the Class 2/3 outer membrane protein. Fragments can be produced by cyanogen bromide cleavage and subsequent purification. Isolated OMV's, the Class I OMP, fragments or oligopeptides can be produced by recombinant DNA techniques, chemical synthesis or chemical or enzymatic cleavage. These materials, in turn, can be conjugated or fused to carrier peptides or proteins, to other antigens of N. meningitidis or to antigens of other microorganisms by chemical or genetic coupling techniques to produce multivalent antigenic conjugates and fusion peptides or
proteins. They can be modified for conjugation such as by the additon of amino acids or other coupling groups. For vaccination, isolated OMV's, the class I OMP, fragments or oligopeptides, in any of the forms described, can be formulated in pharmaceutically acceptable vehicles with optional additives such as adjuvants.
This invention also pertains to isolated nucleic acids which encode class I OMP, fragments or oligopeptides. The nucleic acids can be incorporated into appropriate expression systems for production of isolated OMV's, Class I OMP, fragments or any oligopeptides derived therefrom. These nucleic acids can be modified as genetic fusions to contain sequences encoding additional polypeptides useful in enhancing the immune response to the vaccine formulation containing the expressed fusion polypeptides. In addition, Class I OMP of N. meningitidis is homologous in amino acid sequence and structure to porin proteins of other gram negative pathogens and thus the Class I OMP, fragments and oligopeptides of this invention allow for the development of vaccines for other gram negative pathogens.
Brief Description of the Figures
Figure 1. Scheme for amplification of genes encoding meningococcal Class I outer membrane protein by PCR (Polymerase Chain Reaction).
Figure 2. 5' gene sequences encoding VR1
(first variable region) of Class I outer membrane proteins of several N._meningitidis subtypes.
Figure 3. 3' gene sequences encoding VR2
(second variable region) of Class I outer membrane proteins of several N. meningitidis subtypes.
Figure 4. Epitope scanning by reaction of monoclonal antibodies with solid phase decapeptides spanning the predicted amino acid sequences of Class I proteins from strains P1.7, 16, P1.16 and P1.15. Adjacent decapeptides differ by five amino residues. Annotations show the strain from which the sequence was derived, the mAb used and its subtype
specificity.
Figure 5. Reaction of the monoclonal
antibodies with series of overlapping decapeptides corresponding to variable regions VR1 and VR2 , with adjacent p ep tides differing by a single amino acid residue. Annotations show the strain from which the sequence was derived, the mAb used and its subtype specificity. Figure 6. Construction of recombinant
flagellins expressing variable region epitopes of N. meningitidis Class I OMP subtype P1.6, 16.
Figure 7. Structure of recombinant flagellins expressing variabvle region epitopes of N.
meningitidis Class I OMP subtype P1.6, 16.
Figure 8. Representative chromotogram of high performance liquid chromatography of a recombinant flagellin.
Figure 9. Representative analysis by SDS-PAGE of recombinant flagellin.
Figure 10. Regresentative Western blot
analyses of a conjugate comprising an epitope of N.Meningitidis Class I OMP conjugated to CRM 197.
Figure 11. Putative conformation of N.
Meningitidis Class I OMP subtype P1.16.
Detailed Description of the Invention
This invention pertains to vaccines comprising isolated OMV's, meningococcal Class 1 OMP, fragments of the OMP (e.g., prepared by the application of cyanogen bromide ) and oligopeptides bearing epitopes of the OMP; the preparation of isolated OMV's, pure Class 1 outer-membrane proteins, using mutant strains which do not express the Class 2/3 outer-membrane protein; the preparation of isolated OMV's pure Class 1 outer-membrane proteins with the aid of cloned DNA in recombinant DNA expression vectors. This invention also comprises the application of genetic engineering with the object of producing isolated OMV's Class I OMP or portions thereof, genetic fusions of Class I OMP, portions or epitopes therof; and the preparation of multivalent Class 1 outer-membrane vaccine through peptide synthesis, as the epitopes with a short peptide chain can be synthetically prepared.
It has emerged that meningococcal Class 1 outer-membrane proteins induce a strong bactericidal immune response to the strains containing the appropriate subtype epitopes, irrespective of whether these are from group A, B , C , W- 135 , and Y strains. The polysaccharide vaccine can be enhanced or replaced by a vaccine according to the invention as a vaccine with broad, extensive action against most serotypes. The protective bactericidal monoclonal antibodies specific for the Class 1 outer--membrane protein react strongly with fragments that have been split off and short synthetic peptides which have been prepared using the amino acid sequence of Class 1 outer-membrane proteins. Since meningococcal disease is currently caused chiefly by group B meningococci and because the Class 1 outer--membrane proteins occurring in group B meningococci also occur in group A, C, W-135, Y meningococci, vaccines of this invention which comprise one or more Class 1 OMP epitopes derived from N.
meningitidis group B should be effective in preventing disease caused by group A, C, W-135 and Y.
Preferably, the preparation of such a vaccine starts from at least two different immunogenic and protective epitopes which have been selected on epidemiological grounds. Vaccines according to the invention comprise, for example, at least one protein which is obtained either in OMV formulation or by purification from mutant strains producing one or more Class I OMP or at least two fragments prepared through a cyanogen bromide fragmentation or at least two synthetic peptides, chosen from about 10 major epitopes, or products obtained by gene expression via recombinant DNA technology, which contain the desired epitopes. To maximize efficacy to a broad range of meningococcal strains, the greater number of different protective epitopes in the vaccine the better. In addition, the vaccines according to the invention may advantageously contain meningococci A and C or optionally W-135 and Y polysaccharides and/or detergents. Preferably, the A and C polysacchar ides are convalently coupled to a protein or polypeptide carrier. These carriers include, for example, isolated OMV, the Class I OMP protein, T-helper epitopes, bacterial toxins, toxoids, nontoxic mutants (CRM's), recombinant
Salmonella flagellin and viral particles such as rotavirus VP6 protein, Hepatitis B surface antigen or parvovirus VP1 and VP2 p ro te ins . Bo th Zwi t te r i ono gen i c , c at iono genic, anionogenic and nonionogenic detergents can be used. Examples of such detergents are Zwittergent 3-10, Zwittergent 3-14 (N-tetradecyl-N, N-dimethyl-3-ammonia-1-propane sulphonate), Tween-20, sodium deoxycholate, sodium cholate and octylglucoside. The vaccines according to the invention may also contain an adsorbent such as aluminium hydroxide, calcium phosphate; or advantageously, aluminium phosphate. The fragments, proteins, peptides can also be processed in immunostimulating complexes (ISCOMS), liposomes or
microspheres for delivering and/or use as an
adjuvant or in connection with other adjuvants so that greater immunogenicity is obtained.
This invention encompasses isolated OMV, substantially pure meningococcal class 1 outer membrane proteins (of any subtype) and fragments of the proteins containing epitopes thereof. The fragments can be any portions of the molecular weight of 25kD or less which contain epitopes which are bound by protective bactericidal antibodies against N. meningitidis. These include proteolytic fragments and synthetic oligopeptides which are comprised of amino acid sequences which correspond, at least in part, to epitopes of a Class I OMP.
The isolated OMV's, Class I OMP, fragments or epitope-containing oligopeptides derived therefrom can be comprised of amino acid sequences which are different, but essentially biologically equivalent to the natural sequences. These sequences can include sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For examp le , the nonp o l ar ( hydrophob ic ) amino acids include glycine, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic and glutamic acids.
Additionally, isolated OMV's, the class I OMP, fragments or the oligopeptides can be modified for conjugation to other molecules (e.g., by the
attachment of coupling groups such as the amino acids cysteine and/or lysine or other linking groups and/or spacer groups) including other class 1 OMP of a different subtype, T cell epitopes, B cell
epitopes, carrier peptides or proteins or
adjuvanting molecules.
As described in detail below, the Class I OMP. fragments or oligopeptides can be used in many different forms (e.g., alone, in mixtures, or as conjugates and genetic fusions produced from recombinant DNA vectors) in vaccines. For these purposes, the materials can be produced by isolation from N. meningitidis, by proteolytic digestion, by chemical synthesis, or by expression as recombinant molecules. The methods of production and use of the isolated OMV's, the class I OMP and the fragments and the oligopeptides of class 1 OMP are described below. Protein modeling and structure analysis of the Class I OMPs were performed using the principles for several E. coli outer membrane proteins. (Vogel, H. et al., J. Mol. Bio., 190:191 (1986); Ference, T. etal . , J. Mol. Bio., 201:493 (1988) and Tommassen, J. in "Membrane Biogenesis", NATO ASI Series H16, pp351, Springer-Verlag, NY (1988)). The derived amino acid sequence of the Class I OMPs were used for the modeling studies and comparison. The amino acid sequence homology was compared to other gram negative bacterial porin proteins and similarity was established for the protein structure. Exposed surface loops and transmembrane structure were very similar for these porin proteins. With the
information revealed concerning variable and
constant region protective epitopes of N.
meningitidis and their structure, one can predict based upon the amino acid sequence where protective epitopes may reside for other pathogenic gram negative bacteria to be evaluated and included in vaccines for the same.
Production of isolated OMV's
OMV's can be produced either from the culture supernatant or from the bacterial cells after fragmentation as described by Beuvery et al. (1983) loc. cit. OMV's carrying proteins from more than one meningococcus can be isolated from strains manipulated to express heterologous proteins. Production and Purification of Class I OMP and CNBr fragments thereof
Class 1 and Class 3 outer membrane proteins can be isolated as described by Beuvery, E.C. et al ., Antonie wan Leeuvenhoek J. Microbiol. 52: 232 (1986). The production of substantially pure Class I OMP free of Class 2 or 3 OMP's is achieved by this method using mutant meningococcal strains which do not express Class 2/3 OMP. A preferred strain for production of Class I OMP is the HIII5 strain, deposited as CBS 636.89.
Fragments can be produced by cyanogen bromide cleavage as described by Teerlink T. et al., J. Exp. Med . 166:63 (1987) for a gonococcal protein. The N-terminal fragment is referred to as CB-1 and the C-terminal fragment is referred to as CB-2. These
CNBr fragments can be purified via reverse phase
HPLC on a VydaxTM C4 or an AquaporTM R-300 column using a water/acetonitrile gradient. Alternatively, the fragment can be purified by multiple cold tr ichloroacetic acid precipitations. These procedures remove greater than 95% of interferring contaminants (e.g., buffer salts, detergents and fragment contaminants).
Preparation of fragments and oligopeptides
containing epotopes of class I OMP
A. Preparation by proteolytic digestion
Oligopeptides containing epitopes reactive with bactericidal antibodies against N. meningitidis can be produced by digestion of the class I OMP, CB-1 or CB-2 fragments with proteinases such as endoLys-C, endoArg-C, endoGlu-C and s taphylococcins V8-prote¬ase. The digested fragments can be purified by, for example, high performance liquid chromatograghic (HPLC) techniques.
B. Preparation by Chemical synthesis
Oligopeptides of this invention can be synthesized by standard solid peptide synthesis (Barany, G. and Merrifield, R.B., The Peptides 2:1-284,
Gross, E. and Meienhofer, J., Eds., Academic Press, New York) using tert-butyloxycarbonyl amino acids and phenylacetamidomethyl resins (Mitchell, A. R. e t al . , J. Org . Chem. 43:2845-2852 (1978)) or 9-fluorenylmethyloxycarbonyl amino acids on a polyamide support (Dryland, A. and Sheppard, R.C., J. Chem.
So. Perkin__Trans. I, 125-137 (1986)). Alternatively, synthetic peptides can be prepared by pepscan synthesis (Geysen, H.M. et al., J. Immunol. Methods 03:259 (1987); Proc. Natl. Acad. Sci. USA 81:3998 (1984)), Cambridge Research Biochemicals, Cambridge, U.K. or by standard liquid phase peptide synthesis. The deletion or substitution of amino acids (and including extensions and additions to amino acids) in other ways which do not substantially detract from the immunological properties of the oligopeptide.
C. Preparation by recombinant DNA techniques
The Class I OMP, fragments and oligopeptides which exhibit epitopes of the Class I OMP can be produced by recombinant DNA techniques. In general, these entail obtaining DNA sequences which encode the desired OMP, [Barlow et al., (1989) Mol. Micro., 3:131) fragment or oligopeptide sequences and introducing into an appropriate vector/host expression system one or more similar or different DNA sequences of Class I OMP's where it is expressed. The DNA can consist of the gene encoding the Class I OMP or any segment of the gene which encodes a functional epitope of the OMP. The DNA can be fused to DNA encoding other antigens of N. meningitidis (such as other outer membrane proteins either of the same or different class) or antigens of other bacteria, viruses, parasites or fungi to create genetically fused (sharing a common peptide backbone), multivalent antigens. For example, Class I OMP fragments can be fused to another class 1 outer membrane protein of a different subtype (or fragments or epitopes thereof) of N. meningitidis to yield fusion proteins comprising multiple class 1 outer membrane protein subtype determinants.
Genetic engineering techniques can also be used to characterize, modify and/or adapt the encoded peptides or proteins. For example, site directed mutagenesis to modify an OMP fragment in regions outside the protective domains, for example, to increase the solubility of the subfragment to allow easier purification. DNA can also be manipulated to effect superproduction of OMP fragments or combinations thereof in various organisms. DNA encoding a Class I OMP, fragments or oligopeptides can be synthesized or isolated and sequenced as described by Barlow, A.K. et al. Infect.
Immune 55: 2734-40 (1987) and Barlow, A.K. et al.,Mol. Micro. 3:131 (1989). Class I OMP genes can be amplified from bacterial DNA by the methods of
Mullis and Faloona, (1987) Method. Enzym.
155:335-350, using the primer sequences disclosed herein. Related DNA sequences for class 1 OMP of different subtypes can be obtained by the procedures described and the amino acid sequences deduced.
A variety of host-vector systems can be used to express the oligopeptides of this invention.
Primarily the vector system must be compatible with the host cell used. Host-vector systems include but are not limited to the following: bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus). The expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used.
In order to obtain efficient expression of the cloned DNA, a promoter must be present in the expression vector. RNA polymerase normally binds to the promoter and initiates transcription of a gene or a group of linked genes and regulatory elements (called an operon) . Promoters vary in their
"strength", i.e., their ability to promote transcription. It is desirable to use strong promoters in order to obtain a high level of transcription and, hence, a high level of DNA expression. Depending upon the host cell system any one of a number of suitable promoters can be used. For instance, for E. coli, its bacteriophages or plasmids, promoters such as the lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, and PR or PL promoters of coliphage lambda and others including but not limited to lacUV5, ompF, bla, 1pp and the like, may be used to -direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted DNA.
Bacterial host cells and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operons the addition of specific inducers is necessary for efficient transcription of the inserted DNA; for example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as trp, etc., are under different controls. The trp operon is induced when tryptophan is absent in the growth media; and the PL promoter of lambda can be induced by an increase in temperature in host cells containing a temperature sensitive lambda repressor, e.g., cI857. In this way, greater than 95% of the promoter--directed transcription may be inhibited in uninduced cells. Thus, expression of the recombinant peptide or protein can be controlled. This is important if the expression product of the DNA is lethal or detrimental to the host cells. In such cases, transformants may be cultured under conditions such that the promoter is not induced; then, when the cells reach a suitable density in the growth medium, the promoter can be induced for production of the protein.
One such promoter/operator system is the "tac" or trp-lac promoter/operator system (Russell and Bennett, 1982, Gene 20:2312-243; DeBoer, European Patent Application, 67, 540 filed May 18, 1982). This hybrid promoter is constructed by combining the -35 b.p. (-35 region) of the trp promoter and the -10 b.p. (-10 region or Pribnow box) of the lac promoter (the sequences of DNA which are the RNA polymerase binding site). In addition to maintaining the strong promoter characteristics of the tryptophan promoter, tac is also controlled by the lac repressor.
When cloning in a eukaryotic host cell, enhancer sequences (e.g., the 72 bp tandem repeat of SV40 DNA or the retroviral long terminal repeats or LTRs, etc.) may be inserted to increase transcriptional efficiency. Enhancer sequences are a set of eucaryotic DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Unlike the classic promoter elements (e.g., the polymerase binding site and the Goldberg-Hogness "TATA" box) which must be located immediately 5' to the gene, enhancer sequences have a remarkable ability to function upstream from, within, or downstream from eucaryotic genes; therefore, the position of the enhancer sequence with respect to the inserted DNA is less critical.
Specific initiation signals are also required for efficient gene transcription and translation in procaryotic cells. These transcription and translation initiation signals may vary in "strength" as measured by the quantitiy of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in E. coli
requires a Shine-Dalgarno (SD) sequence about 7-9 bases 5' to the initiation codon (ATG) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include but are not limited to the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.
Any of the methods described for the insertion of DNA into an expression vector can be used to ligate a promoter and other genetic control elements into specific sites within the vector. N. meningitidis sequences for expression can be ligated into an expression vector at a specific site in relation to the vector promoter and control elements so that when the recombinant DNA molecule is introduced into a host cell the foreign genetic sequence can be expressed (i.e., transcribed and translated) by the host cell.
The recombinant DNA vector can be introduced into appropriate host cells (bacteria, virus, yeast, mammalian cells or the like) by transformation, transduction or transfection (depending upon the vector/host cell system). Host cells containing the vector are selected based upon the expression of one or more appropriate gene markers normally present in the vector, such as ampicillin resistance or tetracycline resistance in pBR322, or thymidine kinase activity in eucaryotic host systems. Expression vectors may be derived from cloning vectors, which usually contain a marker function. Such cloning vectors may include, but are not limited to the following: SV40 and adenovirus, vaccinia virus vectors, insect viruses such as baculoviruses, yeast vector, bacteriphage vectors such as lambda gt-WES- l amb da B , Charon 28 , Charon 4A, lambda gt-1-lambda BC, lambda gt-1-lambda B, M13mp7, M13mp8, M13mp9, or plasmid DNA vectors such as pBR322, pAC105, pVA51, pACYC177, pKH47, pACYC184, pUBH110, pMB9 , pBR325, Col E1, pSC101, pBR313, pML21, RSF2124, pCR1, RP4, pBR328 and the like.
Expression vectors containing the DNA inserts can be identified by three general approaches: (1) DNA-DNA hybridization using probes comprising sequences that are homologous to the inserted gene; (2) presence or absence of "marker" gene functions ( e . g. , resistance to antibiotics, transformation phenotype, thymidine kinase activity, etc.); and (3) expression of inserted sequences based on the physical immunological or functional properties of the gene product.
Once a putative recombinant clone which expresses a desired Class I OMP amino acid sequence is identified, the gene product can be analyzed as follows. Immunological analysis is especially important because the ultimate goal is to use the gene products in vaccine formulations and/or as antigens in diagnostic immunoassays. The expressed peptide or protein should be immunoreactive with bactericidal antibodies against N. meningitidis.
This reactivity may be demonstrated by standard immunological techniques, such as radioimmunoprecipitation, radioimmune competition, ELISA or immunoblots. Once the gene product is identified as a Class I OMP fragment or an oligopeptide contain a functional epitope thereof, it can be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for the purification or proteins. Several techniques exist for purification of heterologous protein from prokaryotic cells. See e.g., Olson, U.S. Patent No. 4,518,526, Wetzel, U.S. Patent No. 4,599,197 and Hung et al., U.S. Patent No. 4,734,362. The purified preparation however produced should be substantially free of host toxins which might be harmful to humans. In particular, when expressed in gram negative bacterial host cells such as E. coli or Salmonella, the purified peptide or protein should be substantially free of endotoxin contamination.
Class I OMP, fragments and oligopeptides of this invention can be formulated as univalent and multivalent vaccines. These materials can be used as produced or isolated by the methods described above. They can be mixed, conjugated or fused with other antigens, including B or T cell epitopes of other antigens. In addition, they can be conjugated to a carrier protein as described below for oligopeptides.
When a haptenic oligopeptide is used (i.e., a peptide which reacts with cognate antibodies, but cannot itself elicit an immune response), it can be conjugated to an immunogenic carrier molecule.
Conjugation to an immunogenic carrier can render the oligopeptide immunogenic. The conjugation can be performed by standard procedures. Preferred carrier proteins for the haptenic oligopeptides are toxins, toxoids or any mutant crossreactive material (CRM) of the toxin from tetanus, diphtheria, pertussis, Pseudomonas, E. coli, Staphylcoccus, and
Streptococcus. A particularly preferred carrier is CRM197 of diphtheria toxin, derived from P.
diphtheriae strain C7 ( β 197) which produces CRM197 protein. This strain has ATCC accession no. 53281. Alternatively, a fragment or epitope of the carrier protein or other immunogenic protein can be used. For example, the hapten can be coupled to a T cell epitope of a bacterial toxin, toxoid or CRM. See U.S. Patent Application Serial No. 150,688, filed February 1, 1988, entitled "Synthetic Peptides
Representing a T-Cell Epitope as a Carrier Molecule. For Conjugate Vaccines", the teachings of which are incorporated herein. Other carriers include viral particles composed of Rotavirus VP6, Hepatitis B surface antigen or parvovirus VP1 and VP2.
The peptides or proteins of this invention can be administered as multivalent subunit vaccines in combination with antigens of N. meningitidis or antigens of other organisms. Some of the other organisms include the pathogenic bacteria H.
influenzae, N. meningitidis, B. catarrhalis, N. gonorrheae, E. coli, S. pneumoniae, etc. For example, they may be administered in conjunction with oligo- or polysaccharide capsular components of N. meningitidis. The capsular components can be derived from any of the serological groups,
including A, B, C, D, X, Y, Z, 29E and W135.
Class 1 outer membrane proteins of different subtypes can be used. These may be used in combination to evoke bactericidal antibodies against N. meningitis. For example, a fragment derived from class 1 outer membrane protein of the P1.7.16 subtype can be used together with outer membrane proteins or fragments of outer membrane proteins of other subtypes, such as P1.1, P1.1,16; P1.2; P1.6; P1.9; P1.15; P1.16; or P1.4 (Abdillahi, H. et al. 1988 Micro. Pathog. 4:27) or with meningococcal polysacchar ides in mixtures or as chemical conjugates. For combined administration with epitopes of other outer membrane proteins, they can be administered separately, as a mixture or as a conjugate or genetic fusion peptide or protein. The conjugates can be formed by standard techniques for coupling proteinaceous materials or techniques for coupling saccharide polymers to proteins. Fusions can be expressed from fused gene constructs prepared by recombinant DNA techniques as described.
As mentioned, Class I OMP, fragment or any oligopeptides derived therefrom can be used in conjunction with antigens (e.g., polymer capsules or saccharide units, envelope or surface proteins) of other pathogenic organisms (e.g. bacteria (encapsulated or nonencapsulated), viruses, fungi and parasites). Additional examples of other organisms include respiratory syncytial virus, rotavirus, malaria parasites, and Cryptococcus neoformans.
In formulating the vaccine compositions with the peptide or protein, alone or in the various combinations described, the immunogen is adjusted to an appropriate concentration and formulated with any suitable vaccine adjuvant. Suitable adjuvants include, but are not limited to: surface active substances, e.g., hexadecylamine, octadecylamine, octadecyl amino acid esters, lysolecithin, dimethyldioctadecylammonium bromide), methoxyhexadecylgyIcerol, and pluronic polyols; polyamines, e.g., pyran, dextransulfate, poly IC, carbopol; peptides, e.g., muramyl dipeptide and derivatives, dimethylglycine, tuftsin; oil emulsions; and mineral gels, e.g., aluminum hydroxide, aluminum phosphate, etc., lymphokines and immune stimulating complexes
(ISCOMS). The immunogen may also be incorporated into liposomes, microspheres, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation.
The vaccines can be administered to a human or animal in a variety of ways. These include intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal routes of administration. Live vaccines
The peptide and proteins of this invention can be administered as live vaccines. To this end, recombinant microorganisms are prepared that express the peptides or proteins. The vaccine recipient is inoculated with the recombinant microorganism which multiplies in the recipient, expresses the Class I OMP, fragment or oligopeptide thereof and evokes a Immune response to N. meningitidis. Live vaccine vectors include: adenovirus, cytomegalovirus and preferably, pox viruses such as vaccinia (Paoletti and Panicali, U.S. Patent No. 4,603,112) and attenuated Salmonella strains (Stocker, U.S. Patent No. 4,550,081 and Curtiss et al., Vaccine 6: 155-160 (1988)). In addition, class I OMP epitopes can be incorporated into the flagella of attenuated
bacterial strains.
Live vaccines are particularly advantageous because they lead to a prolonged stimulus which can confer substantially long-lasting immunity. When the immune response is protective against subsequent N. meningitidis infection, the live vaccine itself may be used in a preventative vaccine against N.meningitidis.
Multivalent live vaccines can be prepared from a single or a few recombinant microorganisms that express different epitopes of N. meningitidis (e.g., other outer membrane proteins from other subtypes or epitopes thereof). In addition, epitopes of other pathogenic microorganisms can be incorporated into the vaccine. For example, a vaccinia virus can be engineered to contain coding sequences for other epitopes in addition to those of N. meningitidis. Such a recombinant virus itself can be used as the immunogen in a mulivalent vaccine. Alternatively, a mixture of vaccinia or other viruses, each expressing a different gene encoding for different epitopes of outer membrane proteins of N. meningitidis and/or epitopes of other disease causing organisms can be formulated as a multivalent vaccine.
An inactivated virus vaccine may be prepared. Inactivated vaccines are "killed", i.e., infectivity has been destroyed, usually by chemical treatment (e.g., formaldehyde treatment). Ideally, the infectivity of the virus is destroyed without affecting the proteins which carry the immunogenicity of the virus. In order to prepare inactivated vaccines, large quanitites of the recombinant virus expressing the desired epitopes are grown in culture to provide the necessary quantity of relevant antigens. A mixture of inactivated viruses express different epitopes may be used for the formulation of "multivalent" vaccines. In certain instances, these "multivalent" inactivated vaccines may be preferable to live vaccine formulation because of potential difficulties arising from mutual interference of live viruses administered together. In either case, the inactivated virus or mixture of viruses may be formulated in a suitable adjuvant in order to enhance the immunological response to the antigens. Suitable adjuvants include: surface active substances, e.g., hexadecylamine, octadecyl amino acid esters, octadecylamine, lysolecithin, dimethyl-dioctadecylammonium bromide, N, N-dicoctadecyl-N', N'bis (2-hydroxyethyl-propane diamine), methoxyhexadecylglycerol, and pluronic polyols;
polyamines, e.g., pyran, dextransulfate, poly IC, carbopol; peptides, e . g., muramyl dipeptide and derivatives thereof, dimethylglycine, tuftsin; oil emulsions; and mineral gels, e.g., aluminum hydroxide, aluminum phopshate, and lymphokines.
EXEMPLIFICATION
EXAMPLE 1: Monoclonal Antibodies Against Class I
OMP's and Their Biological Activity Type specific monoclonal antibodies were prepared against various meningococci Class 1 outer-membrane proteins. These monoclonal antibodies recognize the following subtypes: P1,1;
P1, 2; P1, 6; P1, 7; P1, 9; P1, 10; P1, 15; P1, 16; and P1, 17 (now called P1, 14). The monoclonal antibodies are available as "Monoclonal Kit Serotyping Meningococci" from the RIVM, Bilthoven, The Netherlands. All these monoclonal antibodies react with the SDS (sodium dodecyl sulphate) denatured protein when tested by Western blotting. It also emerged that a number of these monoclonal antibodies reacted with a 25Kd CNBr fragment of the 42Kd Class 1 outer-membrane protein (see below). This result implied that the Class 1 outer-membrane protein epitopes are mainly of linear type and can therefore be copied with synthetic peptides. The epidemiological results of tests carried out by the Applicants show that the described monoclonal antibodies can subtype most of the group A,B,C meningococci which suggests a limited heterogenity. Each Class 1 outer membrane protein also appears to contain two individual type specific epitopes (Abdillahi and Poolman, Microb. Pathogen, 1988, 4: pages 27-32; idem FEMS Microbiol. Immunol. 47: pages 139-144).
The purified Class 1 outer-membrane protein (see below), subtype P1, 7.16, originating from the culture of the Class 2/3 free mutant (HIII5) appeared to induce a bactericidal antibody response of 1:64 serum dilution in a dose of 2.5 μg in mice.
The monoclonal antibodies against meningococci Class 1 outer-membrane proteins, Class 2/3 outer-membrane proteins and lipopolysacchar ides were compared as to bacteridical effect. The monoclonal antibodies against the Class 1 outer-membrane proteins appeared to possess the strongest bactericidal activity (see Table 1). The bacterial response was determined as per Poolman, J.T. (1985), in Schoolnick, G.J. et al. Eds. 'The Pathogenic Neisseriae' ASM Publications, Washington, D.C., page 562. TABLE 1
Bactericidal activity of a collection of monoclonal antibodies, directed against the Class 1 (cl 1),
Class 2/3 (cl 2/3) and lipopolysaccharide (LPS) of meningococci. (ND = not determined).
Test strain Bactericidal activity of antibody pool (titre) strain (Gp:serotype: C1 2/3 pool C1 1 pool LPS pool subtype:LPS type)
3006 (B:26:P1.2:L2) 1000 8000 ND
M981 (B:4P1.-:L5) 10 ND 2000
M990 (B:6:P1.6:L/) 10 2000 ND
M978 (B:8:P1.1:L1.8) ND 8000 1000
M982 (B: 9:P! .9:L3.7) 500 2000 1000
H355 (B:15:P1.15:L1.8) 1000 8000 1000
H44/76 (B:15:P1.7.16:L3.7) 1000 8000 4000
The bactericidal activity of these monoclonal antibodies appears to correlate well with the in vivo protective activity as measured in the rat meningitis model of Saukkonen et al., 1987, Microbial Pathogen 3: 261.
EXAMPLE 1A: Construction_of_meningococcal strains carrying multiple Class 1 genes
Replacement of chromosomal genes by clones, slightly different versions has been described for Neisseria gon o rrh o ea. (Stein, D.C., Clin.
Microbiol. Rev. 2 (Suppl.), S146-S149 (1989).) We have found that this method can be applied to the Class 1 gene in Heisseria meningitidis. This was done in the following way:
(i) The Class 1 gene of strain 2996 (subtype P1.2) was cloned into the vector pTZ19R. (Mead, D.A. et al., Protein Engineering 1, 67 (1986).) The complete gene is located on a 2.2 kb XbaI fragment that was ligated to XbaI digested vector DNA.
(ii) The resulting plasmid was used for
transformation of strain H44/76 (subtype
P1.7, 16). Cells of the acceptor strain were incubated with plasmid DNA in the presence of Mg2+ and normal meningoccal medium; they were subsequently diluted and plated, and the resulting colonies were tested for their ability to bind P1.2 - specific monoclonal antibody. Such transformants were found with a frequency of approximately 10-3. Further characterization showed that replacement of the
H44/76 Class 1 gene had indeed occurred.
An essential feature of the method is the presence of the donor gene on a circular plasmid DNA molecule that is not able to replicate in N . meningitidis, since the use of linearized DNA yielded no transformants at all.
Construction of a strain with two Class 1 genes was done by a modification of the method described above. For this purpose, the P1.2 Class 1 gene was inserted into a clones Class 5 gene. The Class 5 gene family has two features which make it
particularly suitable for this construction.
(Meyer, T.F. and Van Putten, J.P.M., Clin.
Microbiol. Rev., 2 (Suppl.) S139-S145 (1989): (i) there are four or five Class 5 genes present in the meningococcal genome, and (ii) expression of these genes is not necessary for growth under laboratory conditions. A Class 5 gene was cloned from strain H44/76 and the P1.2 gene was inserted into an SphI site located in or very close to the Class 5 gene. The resulting hybrid plasmid, pMC22, was used for transformation of strain HIII5, a Class 3-deficIent mutant of H44.76. Colonies reacting with the
P1.2 - specific monoclonal antibody were isolated and characterized. Out of 10 such transformants, nine were found to have lost the P1.16 epitope of the acceptor strain. This indicates that in all these cases recombination has only occurred between the Class 1 genes, resulting in subtype replacement. However, one transformant was found which made both Class 1 subtypes, i.e., P1.7, 16 and P1.2, suggesting that recombination between the Class 5 gene
sequences on plasmid and chromosome must have occurred. This was confirmed by Western blotting, which revealed the presence of both types of Class 1 protein and by Southern blotting, which demonstrated the acquisition of a second Class 1 gene.
By continuing this construction with other Class 1 subtypes, it is possible to make a strain with four or five different Class 1 genes. The same Class 5 gene can be used in each subsequent
transformation step, the different Class 5 genes can be clones and used separately. These recombinant strains can be used to prepare mixtures of different purified Class I OMPs.
EXAMPLE 1B : Purification of isolated OMV's from bacteriological culture
The purification is carried out according to Beuvery et al. (1983) loc. cit.
This culture can be done with the desired wild type strains, mutant meningococci strains without Class 2/3 outer-membrane proteins and/or homologeous and heterologeous recombinant microorganisms which express one or more of the desired meningococci Class 1 outer-membrane protein and/or epitopes by overproducing vectors either through or not through existing open reading frames and/or manipulated reading frames so that fusion proteins or proteins with exchanged epitopes can be prepared.
Readily available of wild strains are:
H44/76 (B:15:P1,7.16) (Holten E., Norway, deposited as CBS 635-89); 187 (B:4:P1,7) (Etienne J., France); M1080 (B:1:P1,1.7) (Frasch C, USA); Swiss 4
(B:4:P1,15) (Hirschel B., Switzerland); B2106I
(B:4:P1,2) (Berger U., West-Germany); 395
(B:NT:P1,9) (Jonsdottir K., Iceland): M990
(B:6:P1,6) (Frasch C, USA); 2996 (B:2b:P1,2) RIVM, The Netherlands; M982 (B:9:P1,9) (Frasch C, USA); S3446 (B: 14: P1, 6) (Frasch C, USA); H355
(B:15:P1,15) (Holten E., Norway); 6557 (B:17:P1,17) (Zollinger W., USA) and B40 (A:4:P1,10) (Achtman M., West-Germany). An example of a Class 3 negative mutant is HIII5 (B:-:P1.16) deposit # CBS 636.89.
These strains were inoculated from precultures at -70°C into shake flasks and transferred from these into 40, 150 or 350 litre fermenter cultures. The semisynthetic medium had the following composition: L-glutamic acid 1.3 g/l, L-cysteine.HCl 0.02 g/l, Na2HPO4.2H2O 10 g/l, KCl 0.09 g/l, NaCl 6 g/l, NH4Cl 1.25 g/l, MgSO4.7H2O 0.6 g/l, glucose 5 g/l, Fe(NO3)3 100 μM, yeast dialysate. During culturing in the fermenter, the pH and PO2 were monitored and automatically regulated to a pH of 7.0-7.2 and an air saturation of 10%. The cells were grown to early stationary phase harvested by means of centrifuging and washing with sterile 0.1 M NaCl and stored at -20°C or freeze-dried.
EXAMPLE 2: Purification of class 1 outer-membrane proteins from bacteriological culture
This culture can be done with the desired wild type strains, mutant meningococci strains without Class 2/3 outer-membrane proteins and/or homologeous and heterologeous recombinant microorganisms which express one or more of the desired meningococci Class 1 outer-membrane protein and/or epitopes by overproducing vectors either through or not through existing open reading frames and/or manipulated reading frames so that fusion proteins or proteins with exchanged epitopes can be prepared.
Readily available of wild strains are:
H44/76 (B: 15 :P1, 7.16) (Holten E., Norway, deposited as CBS 635-89); 1JT7 (B:4:P1,7) (Etienne J., France); M1080 (B:1:P1,1.7) (Frasch C, USA); Swiss4
(B:4:P1,15) (Hirschel B., Switzerland); B2106I
(B:4:P1,2) (Berger U., West-Germany); 395
(B:NT:P1,9) (Jonsdottir K., Iceland): M990
(B:6:P1,6) (Frasch C, USA); 2996 (B:2b:P1,2) RIVM, The Netherlands; M982 (B:9:P1,9) (Frasch C, USA); S3446 ( B : 14 : P 1 , 6 ) ( Fras ch C. , USA ) ; H355 (B:15:P1,15) (Holten E., Norway); 6557 (B:17:P1,17) (Zollinger W., USA) and B40 (A:4:P1,10) (Achtman M., West-Germany). An example of a Class 3 negative mutant is HIII5 (B:-:P1.16) deposit # CBS 636.89.
These strains were inoculated from precultures at -70° C into shake flasks and transferred from these into 40, 150 or 350 litre fermenter cultures. The semisynthetic medium had the following composition: L-glutamic acid 1.3 g/l, L-cysteine.HCl 0.02 g/l, Na2HPO4.2H2O 10 g/l, KCl 0.09 g/l, NaCl 6 g/l, NH4Cl 1.25 g/l, MgSO4.7H2O 0.6 g/l, glucose 5 g/l, Fe(NO3)3 100 μM, yeast dialysate.
During culturing in the fermenter, the pH and PO2 were monitored and automatically regulated to a pH of 7.0-7.2 and an air saturation of 10%. The cells were grown to early stationary phase harvested by means of centrifuging and washing with sterile 0.1 M NaCl and stored at -20ºC or freeze-dried.
The bacterial mass was for example extracted with the aid of 0.5 M CaCl2, 1% (w/v) Zwittergent 3-14 (Zw 3-14) and 0.14 M NaCl, pH 4.0, using 100 ml per gram of freeze-dried bacterial mass. The suspension was stirred for 1 hour at room
temperature and then centrifuged (1 hour, 3000 x g), after which the supernatant was collected in a sterile manner. 20% ethanol (v/v) was added to the supernatant and after stirring for 30 min. the product was centrifuged (30 min., 10,000 x g), after which the supernatant was collected aseptically. The supernatant was then concentrated by means of diafiltration in an Amicon Hollow Fiber System (HID x 50, cut off 50,000) and CaCl2 and ethanol were removed. The concentrate was diluted with 0.1 M sodium acetate, 25 mm EDTA , 0.05% Zw 3-14 having a pH of 6.0 to the original volume and then
concentrated again by means of diafiltration. This procedure was repeated five times. The pH of the final concentrate was adjusted to a value of 4.0. 20% (v/v) ethanol was added to the concentrate and, after stirring for 30 min., the product was
centrifuged (30 min., 10,000 x g). The whole proteins are purified with the aid of column chromatography in the presence of detergent, for example Zw 3-14. Often gel filtration over Sephacryl S-300 as well as the ion exchange over DEAE Sepharose is applied (Beuvery et al. (1986) supra). The used extraction method, detergents, column chromatography are not the only applicable method yet only serve as examples and must not be regarded as restrictive.
EXAMPLE_3: Preparaton and Characterization of Class
I OMP_Peptide_Fragments
Cyanogen bromide was used to prepare fragments of meningococci Class 1 outer-membrane proteins.
The purified Class 1 or mixtures of Class 1 or 3 outer-membrane proteins were taken up in 70% (v/v) formic acid and treated with a 10-fold excess of CNBr for 16 hours at room temperature. The CNBr and the formic acid were removed by means of evaporation and replaced by 0.2 M Tris.HCl, 6 M urea solution, pH 7.2. The supernatant was prepurified by means of gel filtration over Sepharyl S-200 and subsequently purified with the aid of TSK-2000 gel filtration via HPLC. Beuvery et al., (1986) supra.
Enzymatic digestion of CB2 fragments
To further delineate the epitopes, the
meningococcal CB2 fragment was subjected to
digestion with EndoArg-C, EndoGlu-C or V-8 and the resulting fragments Isolated by HPLC. Briefly, 20 nMoles of CB2 fragment in 1 ml of 25 mM
phosphate/0.1 mM tris buffer (pH 8.0) containing 3M urea was digested at 37°C with 0.2 nMoles of
EndoArg-C (1mg/ml in distilled water) or 0.22 nMoles of EndoGlu-C or V-8 (1 mg/ml in distilled water) for 14-18 hours. The resulting digested fragments were separated by reverse phase HPLC using a Vydac-C4 column and a trifluoroacetic acid-acetonitrile gradient. The main peak eluted from the EndoArg-C digestion had an apparent molecular weight of 7-9 Kdal while the main peak observed following
EndoGlu-C or V-8 had an apparent molecular weight of 4-6 Kdals. The isolated peaks were subsequently shown by Western blot to react to a pool of
monoclonal antibodies (Adam I, 62-D12-8, MN5-C11G and MN14-C116). The P1.16 epitope appears to be present on the C-terminal CNBr fragment of the Class 1 outer-membrane protein of strain H44/76 (B:15: P1, 7.16).
Further characterisation of the P1, 16 epitope was carried out through amino acid sequence determination of the 17Kd (N-terminal) and 25Kd (C-terminal) CNBr fragments. The C-terminal 25Kd is further fragmented with V8 protease, endoLysC, endoGlu-C and endoArg-C. Fragments which were positive with the P1,16 monoclonal antibody were sequenced as far as possible. The sequences which were obtained are as follows :
N-terminus of whole protein:
DVSLYGEIKAGVEDRNYQLQLTEAQUAAGN...
N-terminus of 25Kd C-terminal CNBr
fragment : (M) PVSVRYDSPEFSGFSGSVQFVPIONS ¬
KSAYTPAYYTKDTNNN...
Fragments which react with P1, 16 monoclonal antibodies were isolated using V8 protease and endoArg-C fragmentation with a molecular weight of 7-9Kd and 4-6Kd respectively. The N-terminal sequences hereof are as follows:
V8 7-9Kd fragment: FSGFSGSVQFVP1QNSKSAYTPAYYTKDTN ... Arg-C 4-6Kd fragment: PVSVRYDSPEFSGFSGSVQFVPIQNSKSAYTPAYYTK...
EXAMPLE 4: DNA Sequences of _Class_ I OMP _ Genes
Amino acid sequences of Class I OMP were deduced from the nucleotide sequence of the structural genes of four meningococci Class 1 OMP's with various subtypes. Comparison with four amino acid sequences enabled a prediction of the composition and the location of these epitopes. Further, the P1, 7 and P1, 16 epitopes were confirmed with the aid of peptide synthesis and the demonstration of binding of the . respective monoclonal antibodies.
Class I OMP genes were cloned into lambda gtll (as described for P1, 16 in Barlow et al., (1987)
Infect. Immun. 55 : 2743 - 2740) and subcloned in M13 sequencing vectors and the DNA sequence was determined by standard chain termination dideoxynucleotide techniques.
The complete derived amino acid sequence for P1, 16; P1, 15, P1, 7.16; and P1, 2 proteins are as follows;
10 20 30 40 50P1 . 16: DVSLYGEI KAGVEGRNIQAQLTEQPQVTNGVQGNQV - - KVTKAKSRIRTKIS
** * ************* * **** ***** **** *** *P1 . 15: DVSLYGEIRAGVEGRNFQLQLTEPP-SKSQP- - -QV - -KVTKAKSRIRTKIS
**************** * **** ************* P1 . 7.16 : DVSLYGEIKAGVEGRNYQLQLTEAQAANGGASGQVKVTKVTKAKSRIRTKIS
**************** * **** *************P1 . 2 : DVSLYGEIKAGVEGRNIQLQLTEPLQNIQQPQ - - - - - - - VTKAKSRIRTKIS
**************** * **** ************* 60 70 80 90 100 110
DFGSFIGFKGSEDLGEGLKAVWQLEQDVSVAGGGASQWGNRESFIGLAGEFGTLRAGRVA
*************** ******************* ******* ***************
DFGSFIGFKGSEDLGEGLKAVWQLEQDVSVAGGGATQWGNRESFVGLAGEFGTLRAGRVA
*************** ******************* ******* ***************
DFGSFIGFKGSEDLGDGLKAVWQLEQDVSVAGGGATQWGNRESFIGLAGEFGTLRAGRVA
*************** ******************* ******* ***************
DFGSFIGFKGSEDLGEGLKAVWQLEQDVSVAGGGATRWGNRESFVGLAGEFGTLRAGRVA
*************** ******************* ******* ***************
120 130 140 150 160 170 NQFDDASQAINPWDSNNDVASQLGIFKRHDDMPVSVRYDSPEFSGFSGSVQFVPAQNSKS
******* ** ****************************** ************ *****
NQFDDASQAIDPWDSNNDVASQLGIFKRHDDMPVSVRYDSPDFSGFSGSVQFVPIQNSKS
******* ** ****************************** ************ *****
NQFDDASQAIDPWDSNNDVASQLGIFKRHDDMPVSVRYDSPEFSGFSGSVQFVPIQNSKS
******* ** ****************************** ************ *****
NQFDDASKAIDPWDSNNΛTVASQLGIFKRMDDMPVSVRYDSPEFSGFSGSVQFVPAQNSKS
******* ** ****************************** ************ *****
180 190 200 210 220 230
AYKPAYYTKDTNNNLTLVPAVVGKPGSDVYYAGLNYKNGGFAGNYAFKYARHANVGRNAF
** ** ************************** ************* **
AYTPAHYTRQNNTDV-FVTAWGKPGSDVYYAGLNYKNGGFAGSYAFKYARHANVGRDAF ** ** ************************** ************* **
AYTPAYYTKNTNNNLTLVPAWGKPGSDVYYAGLNYKNGGFAGNYAFKYARHANVGRNAF
** ** ************************** ************* **
AYTPAHFVQQTPQQPTLVTAWGKPGSDVYYAGLNYKNGGFAGNYAFKYAKHANVGRDAF
S+
** ** ************************** ************* ** 240 250 260 270 280 290
ELFLIGSATSDEAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENGDKAKTKNSTT
**** ** ** ************************************* * *******
ELFLLGS-TSDEAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENGDKAKTKNSTT **** ** ** ************************************* * *******
ELFLIGS-GSDQAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENGD--KTKNSTT **** ** ** ************************************* * *******
ELELLGS-GSDEAKGTDPLKNHQVHRLTGGYEEGGLNLALAAQLDLSENAD-- KTKNSTT **** ** ** ************************************* * *******
300 310 320 330 340 350
EIAATASYRFGNAVPRISYAHGFDLIERGKKGENTSYDQIIAGVDYDFSKRTSAIVSGAW
************************ ***********************************
EIAATASYRFGNAVPRISYAHGFDLIERGKKGENTSYDQIIAGVDYDFSKRTSAIVSGAW
************************ ***********************************
EIAATASYRFGNAVPRISYAHGFDFIERGKKGENTSYDQIIAGVDYDFSKRTSAIVSGAW
************************ ***********************************
EIAATASYRFGNAVPRISYAHGFDFΓERGKKGENTSYDQIIAGVTDYDFSKRTSAIVSGAW
************************ ***********************************
360 370
LKRNTGIGNYTQINAASVGLRHKF
************************
LKRNTGIGNYTQINAASVGLRHKF
************************
LKRNTGIGNYTQINAASVGLRHKF
************************
LKRNTGIGNYTQINAASVGLRHKF
************************ + Note this amino acid 15 is located between
A.A.S.184 and 185 of this sequence EXAMPLE 5: DNA_Sequencing_of_Class I OMP Genes from different N. meningitidis Serosubtypes
The Polymerase Chain Reaction (PCR) technique of Mullis and Faloona (Methods in Enzymol. 155:335--50, 1987) was used to amplify the entire Class I
OMP gene and specific fragments according to the
scheme shown in figure 1.
Primers were synthesized on an Applied Biosystems 380B DNA synthesizer and used in standard PCR
30 cycle amplification reactions using Taq polymerase in a Thermal Cycler ( Perkin-Elmer Cetus,
Norwalk, CT) according to the recommendations of the Supplier. Amplified fragments of about 1300, 900 and 450bp were generated from each serosubtype
genomic DNA preparation from the primer combinations shown in Figure 1. The primers used had the following sequences:
PR1: (41 bases with universal primer extension)
TGT AAA ACG ACG GCC AGT TTG AAG ACG TAT CGG GRG TTT GC
PR2: (42 bases with universal primer extension)
TGT AAA ACG ACG GCC AGT GGC GAA TTC GGT ACG CTG CGC GCC
PR3: (42 bases with universal primer extension)
TGT AAA ACG ACG GCC AGT CAT CAG GTA CAC CGC CTG ACG GGC
PR4 : (40 bases with universal primer extension) TGT AAA ACG ACG GCC AGT GCA GAT TGG CAG TCA GAT TGC A
PR5: (40 bases with universal primer extension)
TGT AAA ACG ACG GCC AGT GGG ATC GGT ACC TTT GGC TTG A
PR6 : (40 bases with universal primer extension)
TGT AAA ACG ACG GCC AGT AAC TGA TTC GCA ACG CGA CCG G
FWD: (24 bases)
TTG AAG GAC GTA TCG GGT GTT TCG
REV: (23 bases)
GCA GAT TGG CAG TCA GAT TGC TT
Excess single stranded template for sequencing was synthesized in an 'asymmetric PCR' amplification using 100x excess of primer carrying an 18 base extension at the 5' end corresponding to the universal fluorescent sequencing primers used with an
Model 370A Automated DNA Sequencer (Applied Biosystems, Foster City, CA). Taq polymerase was used in a Standard dideoxynucleotide chain termination
sequencing reaction with the PCR generated single stranded Class I gene fragments as templates.
Derived sequences for gene segments of strains
H44/76 (P1.7, 16), M1080 (P1.1,7), H355 (P1.15), 6940 (P1.6), 6557 (P1.14), 870227 (P1.10) and B40 (P1.10) are shown in Figures 2 and 3. EXAMPLE 6: Confirmation of Amino_Acid_Sequences of Class I OMP Subtype Epitopes
From these gene sequences confirmed by direct sequencing of Class I OMP genes, it was deduced that the sequences corresponding to amino acids 24-34 and 176-187 of P1.16 are markedly variable in the four Class I OMP sequences. Three amino acid sequences N-terminal or C-terminal from these positions should also be considered for possible inclusion in these epitopes to allow for maximizing epitope stability presentation and unexpected insertions or deletions in the native protein sequence. Further the DNA and amino acid sequences of other Class I OMPs should be compared with the P1.7, 16 sequence to allow for maximum allignment and epitope prediction. The first variable region epitope and second variable region epitope are called VR1 and VR2 respectively. These regions encode the subtype epitopes as was confirmed with the aid of peptide synthesis and the reaction of the peptides with P1.2; P1.7; P1.15 and P1.16 specific monoclonal antibodies.
A complete set of overlapping decapeptides staggered by 5 amino acids were prepared using the P1.16 protein sequence. The anti- P1.16 monoclonal antibody reacted with the decapeptide YYTKDTNNNL from P1.16 reacted as expected and no other
decapeptide. (Figure 4).
Of overlapping decapeptides provided with a one (1) amino acid sequence shift in the region 24-34 and 176-187 of the Class I OMP of strains H44/76 (P1.7, 16), MC50 (P1.16) and MC51 (P1.15) more than one peptide reacted with the subtype specific monoclonal antibody. In most cases one or more of the group of these overlapping peptides reacted with the subtype specific monoclonal antibody more strongly than others (Figure 5).
These peptides are designated as the VR1 and VR2 epitopes. In the P1.7, 16 strain, the sequence YYTKNTNNNL is present, the change D to N at residue 180 does have some effect on reducing antibody binding. The sequence HYTRQNNTDVF in P1.15 in the same relative position in the protein as the P1.16 epitope and is responsible for binding to the antl-P1.15 monoclonal antibody. AQAANGGASG shows some binding and peptides 1-3 amino acids downstream show far greater binding to the P1.7 monoclonal antibody. Sequence HFVQQTPQSQP of VR2 Is
responsible for binding to the anti-P1.2 monoclonal antibody. It is probable that the sequences
QPQVTNGVQGN and PPSKSQP in the P1.16 and P1.15 proteins also represent epitopes.
Example 6B: Class I OMP Constant Region Epitope
Identification
Peptides forming surface lo op s were prepared and conjugated to tetanus toxoid. A Biolynx 4170 automated peptide synthesizer (Pharmacia/LKB) was used for continuous flow solid-phase synthesis with the following exception. In the last cycle of the synthesis SAMA-OPfp (o.5 mmol) (Drijfhout, J.W. (1989), Ph.D. Thesis, Leiden, The Netherlands) was coupled in the presence of 1-hydroxybenzotriazole (0.5 mmol) for 30 min., using a standard protocol wiht omission of the piperidine-treatment (i.e. the "Fmoc-deblocking step" which in this case would cause undesirable S-deacetylation). These are referred to as SAMA-peptides.
The peptides and their surface region location which were conjugated to TT are as follows:
Name Peptide Region
176 185
LBV 017 XGGYYTKDTNNNL P1.16, loop 4
24 33
018 XGGAQAANGGASG P1.7, loop 1
276 291
024 XGGLSENGDKAKTKNSTTE P1.16, loop 6
245
025a XGGNAFELFLIGSATSDEAKG P1.16, loop 5
223
025b XANVGRNAFELFLIGSATSDEAKG P1.16, loop 5
124 137
026 XGGDSNNDVASQLQIFK P1.16, loop 3
027 XADLNTDAERVAVNTANAHPV Class 2, loop 5
329
028a XGGGKKGENTSYDQ Class 1, loop 7
317
026b XGGERGKKGENTSYDQ Class 1, loop 7
029 XGGVKDAGTYKAQGGKSKTATQ Class 2, loop 1
78 90
030 XGGWSVAEGGASQVGN P1.16, loop 2
352 366
031 XKRNTGIGNYTQINAA P1.16, loop 8
16 34
032 XGGNIQAQLTEQPQVTNGVQGN P1.16, loop 1 Conjugation of SAMA- peptides to tetanus toxoid was performed as follows. A solution of
N-succinimidyl bromoacetate (4.7 mg, 10 μmol) in DMF (100 μl) was mixed with a solution of tetanus toxoid (TT) (20 mg) in 0.1 M. sodium phosphate buffer pH. 7.8 (3.5 ml). After 1h, 1.8 ml of the reaction mixture was subjected to gel filtration using a Sephadex PD-10 column (Pharmacia) equilibrated in 0.1 M sodium phosphate, containing 5mm EDTA (PE buffer) ph 6.1. The bromoacetylated tetanus toxoid was eluted with the same buffer and collected in 3.5 ml. The solution of bromoactylated tetanus toxoid (1.2 ml) was added to the SAMA peptide (4.5 mg. 3 μmol) and deaerated with helium. Next, 150 μ l of 0.2 M hydroxylamine (in PE buffer, pH 6.1) was added. After 16 h remaining bromoacetyl groups were blocked by addition of 2-aminoethanethiol
hydrochloride (4 μmol) in buffer, pH 6.1 (150 μl). After a further period of 16 h, the peptide-TT conjugate was purified by gel filtration over a PD-10 column using PE buffer, pH 6.1, as the eluant. The appropriate fractions were combined and stored at 4°C.
To determine the immunological activity, 25 μg (total protein) per does of a peptide-TT conjugate was injected subcutaneously at weeks 0 and 4 into 6-8 week old NIH outbred mice. (Note: Vaccine LBV 017-TT and LBV 018-TT were used at 10 μg total protein/dose.) Sera were colledted 6 weeks
following the first dose and evaluated for antibody response in an ELISA assay (Beuvery, E.C. et al.
(1983) Infect. and Immun. 40:3690380). The
following antigens were coated into the microtiter wells: Outer membrane proteim (OMP), purified Class I OMP (Poolman, J.T. et al., (1989) Infect. and Immun. 57 : 1005) and the unconjugated peptides.
Bactericidal activity (BC) of sera was also measured (Poolman, J.T. et al., (1985) supra.)
The results are presented in Table 2 below.
TABLE 2
Bactericidal
Vaccine OMC Class 1 OMP Synth Peptide Test
LBV 018-TT 1:900 (0.05)* 1:2700 ND <1:64
LBV 017-TT 1:900 (1) 1:900 ND <1:64
LBV 024-TT 1:100 1:100 1:900 (homol.) <1:64
LBV 025a-TT - 1:100 1:2700 (homol.) <1:64
LBV 025b-TT 1:2700 (4) 1:300 1:8100 (homol.) <1:64
LBV 026-TT - - - (homol.) <1:64
LBV 027-TT - 1:300 1:300 (homol.) <1:64
LBV 028a-TT 1:100 - 1:2700 (homol.) <1:64
LBV 028b-TT 1:100 1:100 1:900 (homol.) <1:64
LBV 029-TT - 1:100 1:8100 (homol.) <1:64
LBV 030-TT - 1:100 1:2700 (homol.) <1:64
LBV 031-TT - .1:100 - (homol.) <1:64
LBV 032-TT - 1:100 1:900 (homol.) <1:64
* numbers in ( ) indicate O.D. level showing
this titer
These data suggest that of the constant surface loops tested of Class 1 and 2 OMPs of N.
meningitidis loop 5 appears to represent at least
one region that will produce antibodies which will
cross-react with Class 1 and Class 2 OMP of many
strains of N. meningitidis. EXAMPLE 7: Construction of recombinant flagellins expressing meningococcal epitopes
To create hybrid flagella containing epitopes from class I meningococcal epitopes, a series of oligonucleotides was designed based on primary protein sequence data and epitope mapping data. Two oligonucleotides based on VR1 or VR2 epitopes of outer membrane P1.7.16 were designed so that they could be cloned in single or multiple copies into a cloning region within the gene for S. muenchen flagellin. Translation termination signals were included on the non-coding strand of the oligonucleotide to facilitate screening by expression of the cloned inserts.
The plasmid vector pPX1650 containing the entire coding region and promoter regions for the structural gene for flagellin H1-d of Salmonella meunchen (deposited at the ATCC, accession #67685) was modified to contain several unique cloning sites suitable for the insertion of either oligonucleotides or gene fragments in each of the three reading frames of the flagellin gene (Figure 6). First, pPX1650 was digested with EcoRV, which cleaves pPX1650 twice, 48 base pairs apart, and religated to yield a plasmid, pPX1651, which has a unique EcoRV cloning site and which results in a 16 amino acid deletion in the flagellin protein. pPX1651 was identified by screening E. coli recombinants on Western blots probed with polyclonal antibody directed against H1-d flagellin. pPX1651 was identified amongst several candidates having
flagellins smaller than wild type flagellin (of 1650) and was verified by sequencing. Second, pPX1651 was restricted with BamHl and religated after filling out the overhanging ends with Klenow enzyme to remove the unique BamHl restriction enzyme site in the polylinker region of the vector. As a final step, the resulting vector was digested with EcoRV and the following oligonucleotide linker was inserted:
5' ATG ATC GAT GGA TTC 3' 3' TAG TAG CTA CCT AAG 5'
Candidates were screened for the newly created BamH sites and several candidates having BamH1 sites were screened for orientation of the linker by double strand DNA sequencing methodology. One candidate having the linker in the above orientation was retained as pPX1647:
5' .... GAT ATC ATC GAT GGA TTC ATC....
EcoRV Clal BamH1
Plasmid pPX1647 (Figure 7) was digested with BamH and either oligonucleotides for VR1 or VR2 were cloned into E. coli cells. Screening for desired recombinants was accomplished by digesting plasmid minilysate DNA with appropriate diagnostic restriction enzymes and screening for expression by probing hybrid flagella for decreased mobility on SDS-PAGE gels with specific flagellar antiserum (H1-d). A number of the resultant clones showed decreased mobility on SDS-PAGE, indicating proper insertion of one or more of the oligonucleotides for VR1 or VR2. Several of each were retained for analysis by DNA sequencing. Clone CB1-2 results from tandem insertion of two copies of the VR1 oligonucleotide and clone CB1-4 results from insertion of four oligonucleotides. Likewise CB2 P contained a single insert of the VR2 oligonucleotide and CB2 W showed the expected trimeric insert, CB2 P clone contained, a single base pair change which resulted in a change from Leu to Phe in the expressed VR2 fusion protein and was not retained for further study. The recombinant flagellin clones in E. coli were probed with monoclonal antibodies
(Abdillahi and Poolman, Microbiol. Pathogenesis 4:27-32, 1988; RIVM, The Netherlands) known to react with either VR1 or VR2 epitopes. Monoclonals Adam-1 (P1.7) and Mn14-C11-6 (P1.7) react with hybrid flagellin containing 2 or 4 tandem inserts of VR1, but do not react with clones containing VR2. The weaker reaction of both monoclonals with CB1-2 than with CB1-4 is likely due to epitope density. By the same token, monoclonals 62 (P1, 16) and Mn5-c11-G (P1.16) react with CB2 W clone, but not with the VR1 inserts. The CB2 P clone fails to react with either VR2 antibody, probably due to the Leu to Phe change. Each of these clones was transformed into an aroA S. dublin strain (SL5927), having a Tn10 insertion in the H1-d locus, to examine the
functioning of the hybrid flagella. Each of the four clones resulted in motile bacteria; motility of the transformants was inhibited by the corresponding monoclonal antibody, including clone CB2 P,
indicating affinity of the VR2 monoclonal for the epitope in intact flagella. This result indicates that epitopes are exposed at the cells surface and are accessible to antibody.
Hybrid flagellin containing both VR1 and VR2 epitopes were created by cleaving either CB1-2, CB1-4, or CB2 W with BamH1 and cloning the heterologous epitope. Clones CB12-7 and CB12-10 result from the in-frame insertion of a single copy of the VR2 oligonucleotide behind either 2 or 4 VR1 tandem inserts, respectively; clone CB21-F arose from the insertion of one copy of the VR1 epitope behind 3 tandem copies of VR2. CB12-7 and CB12-10 are recognized only by VR1 monoclonal antibody and
CB21-F is recognized only by VR2 monoclonal. These results, taken together with DNA analysis revealing predicted sequences, indicate epitope density is too low in the combined hybrids. To create a hybrid flagellin with increased density of both VR1 and VR2 epitopes, CB12-10 was digested with BamH1 and VR2 encoding oligonucleotides were inserted. Clone 12-10-6 contains two further tandem inserts of the VR2 epitope, resulting in a hybrid flagellin molecule in which four tandem copies of VR1 are followed by three copies of VR2. As is shown in Figure 3a and b, three of the hybrid flagellin vaccine candidates have the expected molecular properties. The flagellin (pCB1 x 4) containing 4 copies of VR1 reacts with anti-H1-d (anti-flagellin) and anti-VR1 monoclonal antibodies, but not with anti-VR2 monoclonal antibodies; the flagellin
(pCB2-W) containing 3 tandem copies of VR2 reacts with anti-H1-d and anti-VR2. antibodies, but not with anti-VR1; the combined hybrid containing copies ofVR1 and 3 copies of VR2 reacts with both anti-VR1 and anti-VR2 monoclonal antibodies. The combined hybrid specifie.d motility when introduced into a non-motile recipient S . dublin strain.
As a subunit vaccine, the goal is to obtain suitable initial vaccine candidates in high quantity and high purity. A suitable vaccine candidate can be chosen from the above type constructions based on reactivity to monoclonal antibodies and function of flagella in non-motile Salmonella host strains. A subunit flagellin vaccine may not need to retain all functional aspects of a parental flagellin, but should at least retain surface localization for purification purposes. Several subunit flagellin meningococcal vaccine were chosen from the above described hybrid molecules based on reactivity to monoclonal antibodies and implied surface localization based on restoration of bacterial motility. Three flagellin vaccine candidates contained either 4 tandem inserts of VR1, 3 tandem inserts of VR2, or 4 VR1 inserts followed by 3 VR2 inserts. Because flagellin is a major protein of Salmonella, it is possible to easily purify sufficient material for vaccination studies using techniques established for flagella purification (Logan et al . , J. Bacteriol. 169: 5072-5077, 1987).
EXAMPLE 8: Initial Purification of recombinant
flagellin molecules
The three hybrid flagellin vaccine candidates and a wild type (derived from pPX1650) were inoculated into four-liter baffled Fernbach flasks containing 1 liter of LB broth. Bacterial cultures were incubated at 37ºC with shaking (200 rpm) for 22-24 hr. Under these conditions of culturing, the bulk of the flagella were sloughed from the bacterial cell surface and were localized in the supernatant culture medium. To obtain suitable material, flagella were isolated from 6-8 liters of culture medium. To obtain purified flagellin preparations for vaccination studies, flagellar filaments were harvested from bacterial culture supernatants by the following procedure: Ammonium sulfate was added to culture supernatant so that final solution was 50% saturated; the solution was stirred gently at 4°C for several hours and the precipitated material was collected by centrifugation in a GSA rotor at 5000 rpm for 30 minutes. The collected ammonium-sulfate precipitated material was reconstituted in PBS and dialyzed against PBS at 4ºC for 12-15 hrs. The dialyzed material was subjected to high speed centrifugation at 100,000 x g for 1 hour in an SW-27 rotor to pellet the flagellar filaments. The pelleted material, which consisted primarily of flagellin, was subjected to further purification by the following method.
EXAMPLE 9: HPLC Purificatuon of recombinant
flagellins
To prepare highly purified flagellins,
Salmonella expressing the constructions, in particular pCB12-10-6, was grown as described above and the cells pelleted at 10,000G. The culture supernatant was then precipitated with 50% ammonium sulfate, centrifuged at 10,000G and resuspend in 30 ml PBS. The resuspended pellet was dialyzed against 10mM Tris buffer (pH=8.0) containing 6M urea, ImM PMSF, 2mM NEM, and 5mM EDTA overnight at 4ºC. Dialyzed material was then passed over two DEAE sepharose minicolumns (3.0 ml volume, 4.0 ml eluent over each). The columns were eluted (5X) with 50mM NaCl in 10mM tris (pH=8.0) containing 6M urea and then with 1M NaCl in 10mM tris (pH=8.0) containing 6M urea. The first four elution collections (20 ml) of the 50mM NaCl were pooled and dialyzed against 1.0 liter 10mM Acetate buffer (pH=4.0) in 6M urea at room temperature . The dialyz e d f rac t i ons were then l o ade d onto a TSK SP PW cation exchange HPLC column (75mm x 300mm). The column was eluted with a mobile phase consisting of lOmM Acetate (pH-4.0) containing 6M urea. A gradient 0 - 300mM NaCL was established in 10mM acetate (pH=4.0) containing 6M urea over the 5 - 30 min interval. After 30 mins the gradient went from 300mM to 1M NaCl in lOmM acetate in 6M urea over the next 5 min. The flagellin construct was collected at approximately 24 min. which corresponds to about 200mM NaCl. The fraction was dialyzed against PBS and purity determined on the material was established by Western blots using anti-flagellin antibody. A representative HPLC analysis and SDS-PAGE are shown in figures 8 and 9 respectively.
EXAMPLE 10: Preparation of meningococcal-flagellin glycoconjugate
Group C meningoccal capsular polysaccharide (GCM CPS : lot # 86 NM 01) was prepared essentially according to Bundle et al. Bundel et al., J. Biol . Chem. 249: 4797-801, 1974).
Neisseria mengitidis strain C11 was obtained from the Walter Reed Army Institute (Washington, DC). The strain was precultured twice on sheep blood agar plates, then used for the inoculation of a liquid seed culture medium Neisseria chemically defined medium, NCDM) Kenney et. al., Bull. W.H.O. 37 469-73, 1967). Finally, 40 1 of liquid medium (NCDM) in a fermentor was inoculated with the liquid preculture. The purity of the strain was checked at each stage. After centrifugation, the supernatant was precipitated by addition of Cetavlon to a final concentration of 0.1%, and the insoluble complex re-dissolved in cold 1 M calcium chloride (CaCl2) (Gotschlich et al . , J. Exp. Med. 129: 1349-65, 1969). Ethanol (96%) was added to a final concentration of 25% (v/v). After 1 h, the suspension was
centrifuged (1 h, 50,000 g), the supernatant was collected, and its ethanol concentration was
increased to 80% (v/v). After 1h, centrifugation (20 min, 5,000 g) yielded a precipitate which was washed successively with absolute ethanol, acetone, and diethylether, and then dried in a vacuum
dessicator over phosphorus pentoxide (P2O5) to constant weight. This crude CPS was stored at
-20°C.
In order to obtain a purer preparation, the CPS was then dissolved in sodium acetate buffer (1.10 dilution of a saturated solution, pH 7.0) and extracted four times wiht hot phenol (Westphal et al., Z. Naturforach. 7b: 148-55, 1952). After dialysis of the combined aqueous phases against 0.1 M CaCl2, followed by centrifugation (3-5 h, 100,000 g), a final ethanol precipitation was performed on the clear supernatant, and the
resulting precipitate washed with organic solvents and dried, as described above. The pure CPS was then stored at -20°C.
At each stage of the purification process, the CPS was analyzed for carbohydrate N-acetylneuraminic acid, NANA) ( Svennerhold, Biochim.
Biophys. Acta 24:604, 957), O-acetyl (Hestrin, J. Biol. Chem. 180:249, 1949), and protein (260 nm detection) content, and its molecular weight checked by gel filtration.
Group C meningococcal capsular polysaccharide (GCM CPS) was simultaneously depolymerized and activated via sodium periodate (NalO4) oxidation in aqueous buffer (Anderson et al . , J. Immunol.
137:1181-6, 1986; Eby et al . , Pediat. Res. 20:308A, 1986, Anderson et al . , J. Pediatr. Ill (5):644-50, 1987; Anderson, U.S. Pat. 4,762,713; 1988). The reaction was monitored by high performance gel permeation chromatography (HPGPC) in aqueous eluent, using ultraviolet (UV) and refractive index (RI) detection. The reaction was stopped and the
activated oligosaccharides (GCM OS) were desalted by low pressure gel permeation (GPC) in water, and then lyophilized. A solution was then prepared in water and subsequently frozen for temporary storage. GCM OS and flagellin pCB12-10-6 were mixed in aqueous neutral buffer and the conjugation was initiated by addition of sodium cyanoborohydride (NaBH3CN)
(Anderson, U.S. Patent 4,762,713, 1988; U.S. Patent 4,673,574, 1987; U.S. Patent 4,761,283, 1988). The reaction was carried out for 5 days, while being monitored by HPGPC. It was finally stopped by dialysis/concentration on centrifugal microconcentrators. The final preparation was stored in the cold, in the presence of thimerosal to prevent bacterial growth. The resulting glycoconjugate not only provides a mechanism to present the expressed VR1 and VR2 meningococcal epitopes to the immune system but also serves as a carrier molecule for the presentation of a meningococcal oligosaccharide.
In preparation of the conjugate, the following conditions were employed. Purified flagellin pCB12-10-6 was dissolved in 15% sucrose (3.5 mg/ml) and then stored at -20ºC. GCM CPS (9.7 mg; final concentration: 5 mg/ml) was oxidized by 100 mM NaIO4 in 0.05 M sodium phosphate buffer (pH 6.2 - 6.5) at RT, in the dark, with agitation. Aliquots (100 μl) were withdrawn at regular intervals, the reaction stopped by addition of ethylene glycol (10 μl), and analysis was performed by HPGPC on Waters (Milford, MA) UltrahydrogelTM 250 + 120 (2 columns coupled; 2 x 300 mm x 7.8 mm) in 0.2 M phosphate-saline buffer
(PBS; 0.2 M sodium phosphate, 0.9% NaCl, pH 7.8), at a flow rate of 0.8 ml/min, using UV (206 nm) and RI detection. After 2 h 30 min, the reaction was stopped by addition of ethylene glycol (1/10 of the reaction volume), and the GCM OS were desalted by GPC on Bio-Rad (Richmond, CA) Bio-GelR P-2 (200-400 mesh, 30 cm x 1.5 cm) in water, at about 18 ml/h.
Fractions were collected (1.2 ml) and analyzed for the presence of NANA the carbohydrate N-acetyl neuraminic acid (NANA) (Barry et al ., J. Gen.
Microbiol. 29:335-52, 1962) and aldehydes (Porro et al., Anal. Biochem 118:301-306, 1981). Positive fractions were pooled and lyophilized. Desalted GCM OS (4.7 mg) were then dissolved in water (10 mg/ml) and frozen at -20°C.
Both GCM OS and pCB12-10-6 solutions were analyzed by HPGPC (UV at 206 and 280 nm respectively) before being frozen, and prior to the conjugation. No degradation occurred during storage, as ascertained by the exact similarity of the elution profiles.
GCM OS (2 mg; final concentration: 2.6 mg/ml) and flagellin p.CB12-10-6 (2.3 mg; final concentration: 3 mg/ml) were mixed in a polypropylene tube in 0.4 M sodium phosphate buffer (pH 7.0), and
NaBH3CN was added (12 μmoles) to initiate the conjugation (Anderson, U.S. Patent 4,762,713, 1988; U.S. Patent 4,673,574; U.S. Patent 4,761,283). The reaction mixture was left one day at RT, then 4 days at 35°C, without agitation. The reaction was monitored by HPGPC (UV at 280 nm) at different stages, and finally stopped by dialysis/concentration on microconcentrators. The final preparation was analyzed for NANA (Barry et al . , J. Gen. Microbiol. 29:335-353, 1962) (0.09 mg at 0.12 mg/ml) and protein (Lowry et al . , J. Biol. Chem. 193:265-275,
1951) (1.12 mg; 1.45 mg/ml) content. It was then stored at 4 ° C in the presence of thimerosal (0.01%, w/v) to prevent bacterial growth. The conjugate preparation was also checked by SDS-PAGE (silver nitrate stain) and Western blots analyzes. Several high molecular weight bands appeared on the gel above the pure pCB12-10-6 band and near the stacking well, the latter being an evidence that cross-linking occurred during
conjugation. Western blot analyzes showed that each band was reactive with the antisera used (anti-GCM, -VR1, and -VR2) , proving covalency of the conjugate bonds.
EXAMPLE 11: Conjugation of Meningococcal peptides to CRM and bovine serum albumin
Peptides designated as M20 and M21 were produced on an ABI model-pep tide synthesizer by solid phase synthesis using the tBoc chemistry were coupled to CRM197 (prepared as described by Andersen, U.S. Patent No. 4,762,713) using a bifunctional crosslinking agent, sulfosuccinimidyl (4-iodoacetyl) amino benzoate (Sulfo SIAB; purchased from Pierce) following the modification of a published procedure (Weltman, J.K. et al., (1983) Bio Techniques 1, 148-152). Briefly CRM197 was activated by sulfo SIAB resulting in the formation of an amide bond between SIAB and amino groups of CRM197. After the removal of unreacted crosslinker from the activated CRM by gel filtration, peptide (M20 or M21) containing linking spacer (represented in underlined letters) with carboxy terminal cysteine residue was mixed with activated CRM and incubated at room temperature for 2-4 hours. Following the reaction, the conjugated material was dialyzed extensively against PBS at 4 C.
The sequence of M20 peptide (VR2 epitope) is as follows:
H-Tyr-Tyr-Thr-Lys-Asp-Thr-Asn-Asn-Asn-Leu-Thr-Leu-V-al-Pro-Ala-Gly-Ala-Cys-OH
The sequence of M21(VR1 epitope) peptide is:
H-Ala-Gln-Ala-Ala-Asn-Gly-Gly-Ala-Ser-Gly-Gln-Val-L-ys-Ala-Gly-AIa-Cys -OH .
Conjugated materials were subjected to SDS PAGE, transferred to PVDF membranes (Immobilon, Millipore) and reacted with specific monoclonals which recognize VR1 and VR2 epitopes. Figure 10a and 10b show the western blot analysis of M20 and M21 CRM197 conjugates, against a pool of VR1 and VR2 specific monoclonals (Adam I, G2-D12-8 (P1.7),
MN5-C11-G (P1.16) and MN14-C11-6 (P1.7)).
In order to assay the antibody response to M20 and M21 peptide by enzyme linked immunoassay procedure, BSA conjugates were prepared by using a different bifunctional crosslinking agent, N-Succinimidyl Bromoacetate as described by Bernatowicz and Matsueda (Anal. Biochem. 155, 95-102 (1986)). Covalent coupling of peptide to the protein was confirmed by western blotting of electrophoresed samples as described for CRM197 conjugates.
EXAMPLE 12: Retention of T cell actiyity by M20
and M21-CRM197 conjugates
To determine whether conjugation of the VR1 and VR2 epitopes to CRM197 adversely affect the T cell recognition of the CRM- q7 protein a T cell proliferative assay was performed as previously described by Bixler and Atassi (Immunol. Commun. 12:593,
1983). Briefly, SJL/j mice were immunized with 50 μg of native CRM197 emulsified in CFA. Seven days later, lymph nodes were removed, cultured in RPMI and challenged with various concentrations of proteins (0.05-100.0 μg/ml) and peptides. After 3 days incubation, cultures were pulsed with [3H]-thymidine for 16 hours and then harvested for counting
TABLE 3
T cell responses to meningococcal peptide-CRM197
conjugates.
In Vitro Challenge Maximum observea [3H] Incorporation
μg/ml ΔCPM SI - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Diphtheria toxoid 5 27,510 57
CRM197 50 108,631 221
CRM197 - mock conjugate 100 116,326 236
M21-CRM197 100 182,499 370
H20-CRM197 10 89,972 183
CON A 1 34,316 70
LPS 50 61,579 126
Tetanus toxoid 10 515 2
Background (cpm) - 494 1- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
As shown in Table 3, a comparison of CRM197 with the CRM197-mock conjugate shows that the conjugation procedure by itself did not alter the T cell recognition of the protein. The T cell responses induced by the M20 and M21-CRM197 conjugates were essential equivalent to or greater than the response elicited by CRM197 itself indicating that the recognition of the T cell epitopes on the CRM197 is not adversely affected by the peptide conjugation. The responses to the control materials Con A, LPS and Tetanus toxoid were as expected. EXAMPLE 13: Immunogenicity of conjugate and
recombinant meningococcal b vaccines
Recombinant flagellin expressing the meningococcal VR1 and/or VR2 epitopes were prepared and purified as described in Examples 7 , 8 and 9. In addition, synthetic peptides representing the meningococcal epitopes VR1 and VR2 were synthesized, covalently coupled to the carrier molecule CRM197 and purified as in Example 12. Vaccines were formulated with each of these materials at protein concentrations of 10 or 100 μg/ml for each of the components. The vaccine compositions also included aluminum phosphate at 1 mg/ml or except as noted were compounded with Freund's complete adjuvant or without supplemental material.
To evaluate immunogenicity, outbred Swiss
Webster mice were immunized intramuscularly at weeks 0 and 2 with 1 or 10 μg protein/dose. Sera were collected at two week intervals, pooled for assay, and screened for antibody activity by ELISA to outer membrane complex (OMC), purified OMP (P1.16), VR1 peptide coupled to Bovine serum albumin (M21-BSA), VR2 peptide coupled to BSA (M20-BSA), wildtype flagellin, and to CRM197. The results of the ELISA performed on sera obtained at 6 weeks are shown in Table 4.
TABLE 4
Immunogenicity of recombinant or CRM197 conjugate vaccines containing the meningococcal P1.16 OMP epitopes vR1 and VR2.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
DOSE ELISA TITERS 4 WEEKS AFTER SECONDARY BOOST1
μg OMC P1.16 M21-BSA M20-BSA FLAGELLIN CRM- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - pPx1650 (control wildtype flagellin)2
1 <150 <100 171 100 427,781 ND
10 <150 100 154 <100 468,385 ND pCB1-4
1 532 4,376 4,525 ND 787,120 ND 10 2,034 12,387 17,565 ND 887,861 ND pCB2-W
1 150 308 ND 501 263,143 ND
10 1,350 12,190 ND 5,476 1,493,216 ND
PCB12-10-6
1 615 3,374 4,651 824 299,889 ND
10 1,423 3,666 3,882 2,253 497,622 ND pCB12-10-6 without aluminum phosphate
1 409 739 505 597 139,147 ND
10 450 1,533 817 1,611 358,033 ND
M20-CRM197
1 <150 <100 217 <100 ND 42.27 10 50 <100 150 <100 ND 95.31
M21-CRM197
1 68 249 10,494 100 ND 17.41
10 110 311 26,807 191 ND 20.92
MIXTURE OF M20 AND M21 CONJUGATES
1 50 100 40,000 187 ND 37.32
10 50 227 15,539 132 ND 184.27
OMP P1.16
1 12,630 17,714 100 764 ND ND
10 23,178 67,565 162 3,276 ND ND pCB1-4 in CFA
10 1,665 10,606 19,945 ND 1,841,852 ND pCB2-W in CFA
10 1,157 6,869 ND 17,749 1,217,063 ND - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1 All pre-bleed values at or below the lower limit of assay of 1/100 dilution.
2 All vaccines were formulated with 1 mg/ml aluminum phosphate except as noted. Alternatively, the various vaccines were
evaluated for immunogenici ty in 6-8 week old NIH
outbred mice. The mice were immunized with 100 μg
(total protein)/dose subcutaneously on week 0 and 4
with vaccine and sera was collected on week 6. The
sera were evaluated in an ELISA assay and using
antigens as described in Example 6. Bactericidal
activity was measured as in Example 6. The results
are found in Table 5.
TABLE 5
ELISA (titer > 0.5 OD)
Bactericida
Vaccine OMC Class 1 OMP Synth. Peptide Test FLAGELLIN
p1650 - - - <1: 64 pCB12.10.6 - 1:900 - <1 :64 pCB2-V - 1:300 1: 100 <1 :64 pCB1-4 1:300 (.25) 1:2700 - <1: 64
CRM197 - - - <1 : 64
H20-CRM197 1:00 1:8100 - <1 : 64
H21-CRM197 1:300 (.125) 1:8100 - <1 : 64
The recombinant flagellins containing either a VR1, VR2 or a cassette of both VR1 and VR2 were effective in eliciting an antibody response which was cross-reactive to the purified P1.16 and to a lesser extent to OMC . Sera from animals immunized with 10 μg of either pCB1-4 or pCB2-w induced antibodies which bound to their respective peptide--BSA conjugates as well as cross reacted with the P1.16 and OMC. Similar results were obtained with the constructed pCB12-10-6 which contains both meningococcal epitopes. In addition, each construction induced significant anti-flagellin titers as well. In contrast, the control wildtype flagellin only induced an antibody response to flagellin itself. Sera collected prior to immunization showed no pre-existing response to the materials being evaluated.
The data also demonstrates the benefits of formulating the recombinant flagellins with alum or other adjuvants such as CFA. The construction pCB12-10-6 was formulated with and without the addition of aluminum phosphate. As shown in table 2, pCB12-10-6 alone was capable of inducing an antibody response which react to the peptide conjugates as well as to the purified P1.16 as well as to OMC. In comparison, the same construction when formulated with alum was able to elicit greater antibody response at an equivalent dose. Similarly, the recombinant flagellins pCB1-4 and pCB2-w were also formulated with CFA. Again, equivalent or higher antibody titers were observed in the presence of CFA.
The results of the immunogenici ty studies with the meningococcal VR1 and VR2 conjugates are also shown in Table 4. Both the M20 and the M21-CRM197 conjugates as well as a mixture containing equal amounts of both conjugates were capable of inducing an anti-CRM197 response as well as an anti-Class I OMP response.
These preliminary data, indicate a Class I OMP variable region epitopes either chemically
conjugated to a carrier or genetically fused to a carrier elicit an immune response. New epitope-carrier conjugates can be made using standard techniques to enhance the immune response to the vaccine, for example, use of 1) larger epitopes, 2) peptides with multiple epitope repeats and/or 3) different carriers.
EXAMPLE 14: Preparation of Mrningoccal-human serum albumin glycoconjugate
GCM CPS was depolymerized by acid hydrolysis and GCM OS obtained were subsequently activated via
NalO4 oxidation in aqueous buffer. The reactions were monitored by HPGPC in aqueous eluent, using UV and RI detection. The reactions were each followed by GPC desalting in water. GCM OS and human album in (HA) were mixed and conjugated essentially as described in Example 10 for the miningococaal flagellin glycoconjugate. The final preparation was stored in the cold, in the presence of thimerosal to prevent bacterial growth.
In preparation of the conjugate, the following experimental conditions were employed. Human albumin (HA; SigmaR, St. Louis, MO) was dissolved in 15% sucrose (10 mg/ml) and then stored at -20°C.
GCM CPS (lot # 86 NM 01; 106 mg ; final concentration: 10 mg/ml was hydrolyzed in 0.1 N HCl at 50°C with agitation. Aliquots (25 μl) were withdrawn at regular intervals, the reaction stopped by addition of sodium hydroxide (NaOH) and analysis was performed by HPGPC as described. After 3 h 40 min., the reaction was stopped by addition of NaOH, and the GCM OS were desalted by GPC. Fractions were collected (1.2 ml) and analyzed as described before. Positive fractions were pooled and lyophilized.
Desalted GCM OS (89 mg) were then stored at -20°C. Activated OS were prepared by oxidation of GCM OS (11.8 mg; final concentration: 5mg/ml) with 2 mM NaIO4 in 0.05 M sodium phosphate buffer (pH 6.2-6.5) at RT, in the dark, with agitation. The reaction was stopped after 30 min by addition of ethylene glycol. HPGPC analyzes showed no degradation of the molecular weight of the OS during activation.
Desalting and colorimetric anaylzes were then performed as described above. The resulting
activated GCM OS (8.8 mg) were dissolved in water (10 mg/ml) and frozen at -20°C. Both GCM OS and HA solutions were analyzed by HPGPC (UV at 206 and 280 nm respectively) before being frozen, and prior to the conjugation. No degradation occurred during storage, as ascertained by the exact similarity of the elution profiles.
GCM OS (6 mg; final concentration: 2.5 mg/ml) and HA (12 mg; final concentration: 5mg/ml) were mixed in a polypropylene tube in 0.4 M sodium phosphate buffer (pH 7.0), and NaBH3CN was added (60 μmoles) to initiate the conjugation (Anderson, U.S. Patent 4,762,713, 1988; U.S. Patent 4,673,574, 1987; U.S. Patent 4,761,283, 1988). The reaction mixture was left one day at RT , then 4 days 15 35°C, without agitation. The reaction was monitored by HPGPC (UV at 280 nm) at different stages, and finally stopped by dialysis/concentration on microconcentrators.
The final preparation was analyzed for NANA (Barry et al. , J. Gen. Microbiol. 29P335-51, 1962) (2.07 mg at 0.86 mg/ml) and protein (Lowry et al . , J. Biol . Chem. 193265-75, 1951) (9.51 mg at 3.96 mg/ml) content. It was then stored at 4°C in the presence of thimerosal (0.01%, w/v) to prevent bacterial growth.
The conjugate preparation was also checked by SDS-PAGE (silver nitrate stain) and Western blot analyzes. A diffuse band appeared on the gel which covered a significantly wider molecular weight range than the pure HA. Western blot analyzes showed that this band was reactive with the antiserum used (anti-GCM), proving covalency of the conjugate bonds.
EXAMPLE 15: Immunogenicity of meningococcal
oligosaccharide-recombinant flagellin vaccines
A meningococcal oligosaccharide-recombinant flagellin vaccine was prepared as described above and formulated at 100 μg pro.tein/ml. Vaccine compositions were also prepared which contained aluminum phosphate (1 mg/ml) or complete Freund's adjuvant in addition to the glycoconjugate.
To evaluate the immunogenicity, outbred Swiss Webster mice were immunized intramuscularly with 10 μg protein at week 0 and 2. Sera were collected at weeks 0, 2 and then weekly intervals thereafter to 6 weeks. After collection, pooled sera samples were assayed for antibody activity by ELISA to
meningococcal C oligosacchar ide conjugate to human serum albumin, OMC, P1.16, CB1 and CB2-BSA conjugates and flagellin.
The MenC-CB12-10-6 glycoconjugate was effective at eliciting an immune response which was reactive with both the oligosacchar ide and the meningococcal B OMP epitopes expressed in the recombinant
flagellin. As shown in Table 5B, as little as three weeks into the study, mice immunized with 1 μg of MenC-CB12-10-6 conjugate in complete Freund's adjuvant had detectable antibody to MenC-HSA, OMP and to both the CB1 and CB2 epitopes. Further, all of the MenC-CB12-10-6 preparations, regardless of adjuvant, elicited antibody response to MenC-HSA which were greater than the response observed
following immunization with MenC-CRM197.
Table 5B. Immunogenicity of Meningococcal C - recombinant flagellin vaccine one week after
secondary immunization.
ELISA TITERS-
IMMUNOGEN Dose MenC-HSA OMP CBl-BSA CB2-BSA FLAGELLIN
MenC-CB12-10-6 CFA 10 24,530 608 5,240 432 541,467
1 5,069 5,614 5,375 12,685 526,593 alum2 10 11,845 253 835 673 472,766
1 4,415 136 242 244 214,263
None 10 11,497 920 626 2,382 233,307
1 4,920 483 1,123 1,210 135,625
MenC-CRMl97 alum 10 4,905 ND ND ND ND
1 8,505 ND ND ND ND
OMP (P1.16) alum 10 ND 12 ,907 <100 <100 ND
1 ND 10 ,405 <100 3,377 ND
1 Titers for initial prebleed samples (week 0) samples were <100.
2 Aluminum phosphate was used as adjuvant at 1 mg/ml.
EXAMPLE 16: T-cell epitopes of Class I OMP and their identification
An effective vaccine must contain one or more T-cell epitopes. T-cell epitopes within a protein can be predicted as described by Margalit et al . , J .
Immunol. 138 : 2213, (1987) or Rothbard and Taylor, EMBO J. 7:93, (1988). These predictive methods were applied to the amino acid sequence of the Class I OMP of N. meningitidis strains P1.7,16, P1.16 and P1.15. The segments of the sequence containing potential T cell epitopes identified by these methods are shown in Tables 6 and 7. The predicted peptides were synthesized by standard FMOC
procedures, purified by standard methods and were Identified as shown in Table 8.
To determine which of the predicted peptides actual contain T cell epitopes, their capacity to stimulate human peripheral blood lymphocytes (PBL) was tested by lymphocyte proliferative assay.
Briefly, peripheral blood was collected from HLA typed normal volunteers or from volunteers who were previously immunized with MPC-2 (Poolman, J.T. e t al ., Antonie van Leeuwenhoek, 53: 413 - 419 , 1987) which contained P1.16, 15, Class 4 OMP and Group C polysaccharide. Lymphocytes were isolated from the peripheral blood by isolation on Ficoll-Hypaque (Pharmacia Fine Chemicals AB , Uppsala, Sweden) and cultured at 1 X 105 cells/well in supplemented RPMI 1640 (Gibco Laboratories, Paisly, Scotland) containing 10% heat-inactivated pooled human AB serum. Cultures were challenged with various concentrations of the predicted T cell epitopes
(0.05 - 10 μg/ml). After in vitro challenge, the cultures were incubated for six days and then pulsed (18 hours) with 0.5 μCi of [3H]-thymidine. Cultures were then harvested and counted by liquid
scintillation. Data are expressed as stimulation indices which were calculated as a ratio of the CPM obtained in the presence of antigen to the CPM obtained in the absence of antigen.
As shown in Table 9, 10 of the 16 predicted peptides showed some capacity to stimulate T-cells. These include the peptides identified at 16-34, 47-59, 78-90, 103-121, 124-137, 151-158, 176-185, 223-245, 276-291 and 304-322. In some instance, peptides stimulated a response in both immunized as well as non-immune individuals. The response in the non-immune individuals may be attributed to a previous asymptomatic infection.
In the case of the T cell epitope identified as region 176-185, enhancement of the T cell response was observed following addition of the monoclonal antibody MN5C11G (P1.16). Briefly, PBL were
challenged in vitro with a synthetic peptide
containing the region 175-185 or with this peptide mixed with varying dilutions of MN5C11G. As shown in Table 10, enhancement of the T cell response was observed following addition of MN5C11G indicating that monoclonal antibody recognized a B cell epitope within the region 176-185 and facilitates the presentation of the peptide to the immune system.
Thus, it was established that the T and B cell epitopes either coincide or are found on contiguous sequences within the Class I OMP.
In several cases, T cell lines and clones were established from individuals responding to various peptides. Briefly, T cell lines were obtained by culturing isolated lymphocytes in 24 well plates at
1 x 106 cells/ml. The culture medium, supplemented
RPMI-1640 with 10% human serum, also contained 12
U/ml recombinant IL-2 (Boehringer). In addition, 5 x 104 homologous, irradiated (3,000R) antigen presenting cells (APC) were also added to each well.
In some cases, APC were obtained from HLA compatible donors. From the lines, T cell clones were isolated by limiting dilution at a frequency of 0.5
cells/well. Clones were maintained by bi-weekly stimulation with antigen in the presence of
irradiated APC and IL-2 (2 U/ml). Clones were tested by lymphocyte proliferation assay essentially as described above except that clones were cultured at 1 x 104 cells/well in the presence of irradiated
APC.
Clones obtained as described were challenged in vitro with OMP from 7 different strains of
meningococci. As shown in Table 11, the clones recognized a T cell epitope or epitopes common to the seven OMPs examined. Although the reactivity of these clones to the various peptides remains to be determined, the data, nevertheless, does indicate
the commonality of T cell epitopes among the various
strains. Now that these clones have been
established and identified their peptide reactivity
will indicate T-cell epitopes for vaccine use.
Table 6. ANALYSIS Or THE SEQUENCE OF N. MENINGITIDIS P1.16 OMP FOR THE PRESENCE OF AMPHIPATHIC α-HELICIES ACCORDING TO THE METHOD OF MARGALIT ET AL. (J. IMMUNOL. 138:2213, 1987)- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
MID POINTS
OF BLOCKS ANGLES AS
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - P 47-50 85-105 9.4
69-74 105-135 16.0
K 79-88 90-120 23.0
127-135 100-120 22.4
* 199-202 90-120 8.4
P 208-211 85-95 8.7
260-263 90-125 8.8
P 265-269 90-120 11.3
274-277 105-120 9.8
297-300 100-135 9.1
P 320-324 80-100 10.9
* 338-342 105-135 12.3
* 346-351 80-115 11.9
* 376-379 85-120 9.5
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Table 7. PRESENCE Or MOTITS (UNDERLINED REGIONS) REPRESENTING POTENTIAL T CELL EPITOPES WITHIN THE SEQUENCES Or N. MENINGITIDIS
P1.16 OMP AS DETECTED BY THE METHOD OF
ROTHBARD AND TAYLOR (EMBO J 7:93, 1968).
M R K K L T A L V L S A L F L A A V A D V S L Y G E I K A G V E G R N I O A Q L T E Q P Q V T N G V Q G N Q V K V T K A K S R I R T K I S D F G S F I G F K G S E D L G E G L K A V W Q L E Q D V S V A G G G A S Q W G N R E S F I G L A G E F G T L R A G R V A N Q F D D A S Q A I N P W D S N N D V A S Q L G I F K R H D D M P V S V R Y D S P E F S G F S G S V Q F V P A Q N S K S A Y K P A Y Y T K D T N N N L T L V P A V V G K P G S D V Y Y A G L N Y K N G G F A G N Y A F K Y A R H A N V G R N A F E L F L I G S A T S D E A K G T D P L K N H Q V H R L T G G Y E E G G L N L A L A A Q L D L S E N G D K A K T K N S T T E I A A T A S Y R F G N A V P R I S Y A H G F D L I E R G K K G E N T S Y D Q I I A G V D Y D F S K R T S A I V S G A W L K R N T G I G N Y T Q I N A A S V G L R E K F
TABLE 8. SUMMARY OF PREDICITED T CELL EPITOPES SYNTHESIZED, - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - RESIDUE NO. SEQUENCE
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
1. 16-34 NIQAQLTEQPQVTNGVQGN
2. 47-59 TKISDFGSFIGΓK
3. 57-71 GFKGSEDLGEGLKAV
4. 78-90 VSVAGGGASQWGN
5. 103-121 TLRAGRVANQFDDASQAIN
6. 124-137 DSNNDVASQLGirK
7. 151-158 GGΓSGFSG
8. 176-185 YYTKDTNNNL
9. 190-202 AWGKPGSDVYYA
10. 215-228 YAFKYARNAHVGRN
11. 223-245 ANVGRNAFELFLIGSATSDEAKG
12. 241-261 DEAKGTDPLKNHQVHRLTGGY
13. 276-291 LSENGDKAKTKNSTTE
14. 304-322 VPRISYAHGFDLIERGKKG
15. 317-329 ERGKKGENTSYDQ
16. 352-366 KRNTGIGNYTQINAA
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Figure imgf000086_0001
Table 10. PRESENTATION OF A SYNTHETIC PEPTIDE TO PERIPHERAL BLOOD LYMPHOCYTES IS ENHANCED BY A MONOCLONAL ANTIBODY RECOGNIZING REGION 179-184 OF MENINGOCOCCAL CLASS I OMP. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
IN VITRO CHALLENGE CPM
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
GGYYTKDTNNNL 3,017
GGYYTKDTNNNL* + MN5C11G (1:200) 22,836
GGYYTKDTNNNL + MN5C11G (1:1000) 12,608
MEDIA 330- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - * Underline region indicates sequence recognized by monoclonal antibody MN5C11G.
Table 11. RECOGNITION OF OMP FROM DIFFERENT MENINGOCOCCAL STRAINS
BY HUMAN T-CELL CLONES
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
RESPONSE OF HUMAN T CELL CLONES (CPM X 10-3)
STRAIN SUBTYPE 5-5 5-9 5-12 5-13 5-14 5-15- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
H44-76 P1.16 6.0 1.2 6.8 2.6 2.3 9.5 1.5 SWISS 4 P1.15 4.9 1.0 10.1 6.9 3.6 10.5 1.4 395 P1.9 S.2 1.5 4.8 1.5 6.1 13.1 1.4
2996 P1.2 5.4 1.0 3.7 2.3 3.4 11.8 1.0
M990 P1.6 3.6 0.4 3.S 2.5 0.9 4.7 0.6
187 P1.1 4.4 0.7 4.5 3.1 1.6 6.2 1.4
6557 P1.17 3.7 2.0 8.2 4.2 1.7 6.2 0.8
MEDIA <0.1 <0.1 <0.1 <0.1 < 0.1 <0.1 <0.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EXAMPLE 17: Construction of Protein Model for
Membrane Topology of Class I OMP and Comparison to Other Pathogenic Gram
Negative Porin Proteins for Vaccine Development.
A model was constructed using the principles recognized for the structure of several Escherichia coli outer membrane Proteins (Vogel, H. et al.
(1986) supra Ferenci, T. et al. (1988) supra; and Tommassen, J. (1988) supra). The central assumption is that protein segments spanning the outer membrane form beta-sheets. Specifically, in the case of Class 1 protein, the division in exposed and transmembrane segments was arrived at in the following way :
1. A comparison of the amino acid sequence of
Class 1 protein (subtype P1.16) with those of the gonococcal P1A and P1B proteins (Carbonetti, N.H. et al. (1987) PNAS 84:9084; Carbonetti, N.H. et al. (1988) PNAS 85:6841; and Gotschlich, E.C. et al. (1987) PNAS 84:8135) reveals 34% identity. In the model, the variable sequences form the surface-exposed parts, whereas the conserved regions are placed mostly in the outer membrane and periplasm.
Thus, the latter two areas consist for 58% of residues that are conserved among all proteins, 2. The hydrophilic maxima observed in a hydropathy profile (Kyte, J. et al. (1982) J . Mol . Biol .
157: 105) to correspond to exposed regions.
3. The transmembrane segments should preferentially be able to form amphipathic beta-stands of 9-12 residues, with at least one side consisting entirely of hydrophobic residues. These conditions are met in 12 of the 16 membrane-spanning segments.
4. The number of residues at the periplasmic side is minimized.
Figure 11 shows the model for the folding of Calss 1 protein in the outer membrane. The sequence shown is for subtype P1.16. The top part of the figure shows the surface-exposed regions, whereas the central part indicates the presumed transmembrane segments, whose length is set at ten.
Amino acid are shown alternating where they can form an amphipathic beta-strand. This model contains eight surface loops, whereby the first and the fourth loop contain the type-specific and protective variable region epitopes. These epitopes, as has been shown when formulated into a vaccine, can elicit a protective immune response. Loop 5 is constant and has been shown to elicit cross-reactive antibodies to other OMPs and is useful for vaccine formulation. The one or two variable epitope regions of the individual proteins are located on so called surface loops of these membrane proteins. Such porin outer-membrane proteins contain more than two surface loops. This implicates that there are surface loops which have near identical amino acid sequence in the different Class 1 outer-membrane proteins as well. This opens the way to use of common peptides of the Class 1 outer-membrane protein for vaccine
objectives as well. More especially a schematic two-dimensional model of the meningococci Class 1 outer-membrane protein P1, 16 is illustrated in
Figure 11. This model contains eight surface loops, whereby the first and the fourth loop contain the type specific epitopes as shown on the basis of strain subtyping results. The fifth surface loop represents the constant region described above.
Antibody to the constant region of loop 5 appears to react with N. meningitidis OMP complex. The amino sequence of Class 1 OMP, as derived, was compared to the Class OMP of N. meningitidis (Murakami, K. et al., (1989), Infect. Immun., 57:2318) and the porin P1A and P1B proteins of N. gonorrhoeae. With similar principle as used for the Class I OMP modeling, the sequences were aligned as follows:
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Structural similarities are indicated with transmembrane and surface loop regions. With the information now available for Class I OMP and information based on surface loop size, location, intraspecies amino acid homology or heterology of the loop regions of the particular porin protein, predictions of epitopes for incorporation into vaccines for other pathogenic gram negative bacteria including N. gonorrhoeae are possible. Using the same methods employed for Class I OMP, these epitopes can be evaluated for vaccine purposes. Deposit of Microorganisms
The N. meningitidis strain H4476 (B : 15 : P1.7,16) was deposited on December 11, 1989 in the Centraal Bureau voor Schimmelculturen (CBS), Baarn, The
Netherlands and has deposit number CBS 635.89. The N. meningitidis Class 2/3 OMP deficient mutant
HIII-5 was deposited on December 11, 1989 in the CBS, Baarn, The Netherlands and has deposit number CBS 636.89. Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

C LAIMS
1. Vaccine effective against meningococcal
disease, comprising an effective amount of an outer-membrane vesicle isolated from expressing homologous and/or heterologous or at least one meningococcal class I outer-membrane protein or a fragment or oligopeptide containing an epitope thereof.
2. A vaccine of Claim 1, wherein the meningococcal Class I outer-membrane protein originates from a mutant meningococcal strain which is negative for Class 2/3 outer membrane protein.
3. A vaccine of Claim 1, wherein the Class I
outer-membrane protein, fragment or
oligopeptide is produced by a microorganism containing a heterologous gene encoding the Class I outer-membrane protein, fragment or oligopeptide.
4. A vaccine of Claim 1, wherein the Class I
outer-membrane protein, fragment or
oligopeptide is derived from a group
A,B,C,W-135 or Y meningococcus.
5. A vaccine of Claims 1, wherein the Class I
outer-membrane protein, fragment or oligopeptide is derived from a group B meningococcus.
6. A vaccine of Claim 1, comprising 5-10 various group B meningococci class I outer-membrane p ro te ins , fragments o r o l i gopep t ide s .
7. A vaccine of Claim 1, wherein the protein
fragment is obtained by cyanogen bromide treatment of a Class I outer-membrane protein.
8. A vaccine of Claim 1, wherein the fragment of class I meningococcal outer-membrane protein is obtained by proteolysis with an enzyme selected from the group consisting of endoLys-C, endoArg-C, endoGlu-C and S taphylococcus
V8-protease.
9. A vaccine of Claim 1, wherein the oligopeptide comprises at least one bactericidal antibody binding epitope of meningococcal class I outer-membrane proteins.
10. A vaccine of Claim 1, wherein the oligopeptide comprises at least an amino acid sequence selected from the group consisting of
QPQVTNGVQGN, PPSKSQP, QAANGGASG, YYTKDTNNNLTL , YYTKNTNNNLTL, YYTKDTNNNL , YYTKNTNNNL,
HFVQQTPQSQP and HYTRQNNTDVF.
11. A vaccine of Claims 1, wherein the epitope is located in surface loops of meningococcal class I outer-membrane proteins in the area of amino acids 24-34 and 176-187.
12. A vaccine of Claim 1, wherein the Class I
outer-membrane protein, fragment or
oligopeptide is conjugated to a T cell epitope via chemical coupling.
13. A vaccine of Claim 1, wherein the Class I
outer-membrane protein, fragment or
oligopeptide contains a meningococcal
A,B,C, W-135 and/or Y polysaccharide in
conjugate form with the protein product.
14. A vaccine of Claim 1, further comprising the a Zwitterionogenic, cationogenic, anionogenic and/or non-ionogenic detergent.
15. A vaccine of Claim 14, wherein the detergent is selected from the group consisting of
Zwittergent Zw 3-10, Zwittergent Zw 3-±4, Tween-20, sodium cholate, octyl glucoside and sodium deoxycholate.
16. A vaccine of Claim 1, further comprising the an adsorbent selected from group consisting of aluminium phosphate, aluminium hydroxide and calcium phosphate.
17. A vaccine of Claim 1, further comprising an immuno-stimulating complex (ISCOM).
18. A vaccine of Claim 1, wherein the Class I outer membrane protein, fragment or oligopeptide is contained within a liposome.
19. A vaccine of Claims 1, the Class I outer
membrane protein, fragment or oligopeptide is coupled to a lipid.
20. Substantially purified fragment of class 1
outer membrane protein of Neisseria
meningitidis, the fragment having a molecular weight of about 25 kD or less and containing continuous or discontinuous epitopes reactive with bactericidal antibodies against N.
meningitidis.
21. A fragment of Claim 20, wherein the class 1
outer membrane protein is of the subtype
P1.7.16.
22. A fragment of Claim 21, produced by cyanogen bromide cleavage of a class 1 outer membrane protein of N. meningitidis, the fragment having a molecular weight of approximately 25 kD.
23. Oligopeptide containing a B cell epitope of a Class I outer-membrane protein which varies in amino acid sequence amoung different
meningococcal porin proteins.
24. Oligopeptide of Claim 23, containing at least one of the amino acid sequences selected from the group consisting of QPQVTNGVQGN, PPSKSQP, QAANGGASG, YYTKDTNNNLTL , YYTKNTNNNLTL,
YYTKDTNNNL, YYTKNTNNNL, HFVQQTPQSQP and/or HYTRQNNTDVF.
25. Oligopeptide containing an epitope of a Class I outer-membrane protein which is conserved in amino acid sequence amoung different meningococcal porin proteins.
26. Oligopeptide containing a T cell epitope of a meningococcal Class I outer-membrane protein.
27. Isolated nucleic acid encoding meningococcal class I outer-membrane protein or a fragment or oligonucleotide containing an epitope thereof.
28. A method of eliciting a protective immune
response against Neissweia meningitidis, comprising administering a vaccine composition, comprising one or more meningococcal Class I outer membrane proteins or fragments thereof and, optionally, an adjuvant in a pharmaceutically acceptable vehicle.
29. A method of Claim 28, wherein the fragment is conjugated or genetically fused to a T cell epitope, B cell epitope or carrier peptide or protein.
30. A method of Claim 29, wherein the conjugation is through a cysteine or lysine residue coupled to a terminus of the fragment.
31. A method of Claim 29, wherein the carrier is a bacterial toxin, CRM or toxoid.
32. A method of Claim 28, wherein the class 1 outer membrane protein is of subtype P1.7, 16.
33. A method of eliciting a protective immune
response against Neisseria meningitidis, comprising administering a vaccine composition, comprising at least one oligopeptide containing a continuous or discontinuous epitope of a class I outer membrane protein reactive with bactericidal antibodies against N. meningitidis and, optionally, an adjuvant in a pharmaceutically acceptable vehicle.
34. A method of Claim 33, wherein the oligopeptide contains an amino acid sequence selected from the group consisting of QPQVTNGVQGN, PPSKSQP, QAANGGASG, YYTKDTNNNLTL , YYTKNTNNNLTL ,
YYTKDTNNNL, YYTKNTNNNL, HFVQQTPQSQP and/or HYTRQNNTDVF.
35. A method of Claim 33, wherein the pro teo lyt ic fragment is conjugated or genetically fused to a T cell epitope, B cell epitope or carrier peptide or protein.
36. A method of Claim 33, wherein the conjugation is through a cysteine or lysine residue coupled to a terminus of the fragment.
37. A method of Claim 35, wherein the carrier is a bacterial toxin, CRM or toxoid.
38. An antigenic conjugate, comprising a
meningococcal class I outer-membrane protein, a fragment or oligopeptide containing a epitope thereof conjugated to a carrier protein or epitope thereof.
39. An antigenic conjugate of Claim 8, wherein the oligopeptide selected from the group consisting of QPQVTNGVQGN, PPSKSQP, QAANGGASG,
YYTKDTNNNLTL, YYTKNTNNNLTL, YYTKDTNNNL,
YYTKNTNNNL, HFVQQTPQSQP and/or HYTRQNNTDVF.
40. An antigenic conjugate of Claim 39, wherein the antigen carrier protein is a bacterial toxin, CRM or epitope thereof.
41. An antigenic conjugate of Claim 40, wherein the carrier protein is CRM197.
42. A genetic fusion peptide or protein, comprising an epitope of an meningococcal class I
outer-membrane protein fused to a carrier protein, peptide or epitope thereof.
43. A genetic fusion peptide or protein of Claim 42, wherein the epitope is selected from the group consisting of QPQVTNGVQGN, PPSKSQP,
QAANGGASG, YYTKDTNNNLTL , YYTKNTNNNLTL ,
YYTKDTNNNL, YYTKNTNNNL, HFVQQTPQSQP and/or HYTRQNNTDVF.
44. A fusion protein, comprising a flagellin
protein having an amino acid sequence for an epitope of a meningococcal class I
outer-membrane protein inserted within it.
45. The fusion protein of Claim 44, wherein the
amino acid sequence is inserted within the flagellin protein at a region which is
non-essential to function of the flagellin protein.
46. The fusion protein of Claim 45, wherein the
amino acid sequence is inserted into the hyper-variable region of the flagellin protein.
47. A fusion protein of Claim 44, further
comprising a meningococcal capsular oligo- or polysaccharide conjugated thereto.
48. A recombinant gene, encoding a fusion protein of Claims 44.
49. An infectious, recombinant microorganism
capable of expressing a class 1 outer membrane protein of Neisseria meningitidis, or a
fragment or oligopeptide containing a
continuous or discontinuous epitope reactive with bactericidal antibodies against N.
meningitidis
50. A microorganism of Claim 49, wherein the
oligopeptide selected from the group consisting of QPQVTNGVQGN, PPSKSQP, QAANGGASG,
YYTKDTNNNLTL, YYTKNTNNNLTL , YYTKDTNNNL,
YYTKNTNNNL, HFVQQTPQSQP and/or HYTRQNNTDVF.
51. A microorganism of Claim 49, which is a
vaccinia virus, adenovirus, or cytomegalovirus.
52. A microorganism of Claim 49, which is a
bacteria of the genus Salmonella.
53. A microorganism of Claim 49, wherein the
epitope of the meningococcal class I
outer-membrane protein is expressed as a recombinant flagellin.
54. A method of immunizing against Neisseria meningitidis comprising innoculating an individual with the microorganism of Claim 49.
55. A mutant meningococcal strain incapable of
producing Class 2 and 3 outer-membrane protein.
56. The mutant meningococcal strain HIII5, CBS
636.89
57. A mutant meningococcal strain, incapable of
producing Class 2 and 3 outer-membrane protein, transformed with a heterologous gene encoding a non-native Class I outer-membrane protein.
58. A method of identifying vaccine epitopes of a gram negative porin protein, comprising
a. obtaining the amino acid sequence of the porin protein;
b. comparing the amino acid sequence of the porin protein to the amino acid sequence of a meningococcal Class I outer-membrane protein (OMP) to predict the location, size and sequence of exposed surface loop structures of the porin protein based upon the known corresponding structures in the Class I OMP; and c. identifying potential vaccine epitopes in the surface loop structures based upon the predicted location, size and sequence of the structures.
PCT/US1989/005678 1988-12-19 1989-12-19 Meningococcal class 1 outer-membrane protein vaccine Ceased WO1990006696A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP90901397A EP0449958B9 (en) 1988-12-19 1989-12-19 Meningococcal class 1 outer-membrane protein vaccine
JP50166290A JP3436756B2 (en) 1988-12-19 1989-12-19 Vaccine based on class I outer membrane protein of Neisseria meningitidis
DE68921895T DE68921895T3 (en) 1988-12-19 1989-12-19 MENINGOCOCCALES CLASS I EXTERNAL MEMBRANE PROTEIN VACCINE.
FI912965A FI113009B (en) 1988-12-19 1991-06-18 Procedure for Preparing a Vaccine against the Neisseria meningitidis Bacteria and Neisseria meningitidis Strain
NO912369A NO305463B1 (en) 1988-12-19 1991-06-18 Method of Preparing a Vaccine against Neisseria meningitidis, class 2/3 minus mutant of Neisseria Neisseria meningitidis strain, as well as microorganism expressing a fusion protein
DK199101174A DK175788B1 (en) 1988-12-19 1991-06-18 Vaccine against meningococcal diseases, including components thereof, their use and recombinants expressing them
US08/204,808 US7118757B1 (en) 1988-12-19 1994-02-15 Meningococcal class 1 outer-membrane protein vaccine
US08/461,651 US7238345B1 (en) 1988-12-19 1995-06-05 Recombinant microorganism expressing meningococcal class 1 outer membrane protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL8803111A NL8803111A (en) 1988-12-19 1988-12-19 Meningococcus class 1 outer-membrane protein vaccine - useful to immunise against meningococcal disease
NL8803111 1988-12-19
NL8900036A NL8900036A (en) 1988-12-19 1989-01-06 Meningococcus class 1 outer-membrane protein vaccine - useful to immunise against meningococcal disease
NL8900030 1989-01-06
NL8901612A NL8901612A (en) 1988-12-19 1989-06-26 Vaccines against meningococcal infections - contg. outer membrane proteins or fragments
NL8901612 1989-06-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US07691005 A-371-Of-International 1989-12-19
US08/204,808 Continuation US7118757B1 (en) 1988-12-19 1994-02-15 Meningococcal class 1 outer-membrane protein vaccine

Publications (2)

Publication Number Publication Date
WO1990006696A2 true WO1990006696A2 (en) 1990-06-28
WO1990006696A3 WO1990006696A3 (en) 1990-07-12

Family

ID=27352237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/005678 Ceased WO1990006696A2 (en) 1988-12-19 1989-12-19 Meningococcal class 1 outer-membrane protein vaccine

Country Status (10)

Country Link
EP (1) EP0449958B9 (en)
JP (1) JP3436756B2 (en)
AT (1) ATE120093T1 (en)
AU (1) AU640118B2 (en)
DE (1) DE68921895T3 (en)
DK (1) DK175788B1 (en)
ES (1) ES2070312T5 (en)
FI (1) FI113009B (en)
NO (1) NO305463B1 (en)
WO (1) WO1990006696A2 (en)

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004915A1 (en) * 1990-09-17 1992-04-02 North American Vaccine, Inc. Improved vaccine compositions
WO1994008021A1 (en) * 1992-10-02 1994-04-14 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Immunogenic meningococcal lps and outer membrane vesicles and vaccine therefrom
WO1994009822A1 (en) * 1992-10-26 1994-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNIZATION AGAINST NEISSERIA GONORRHOEAE AND $i(NEISSERIA MENINGITIDIS)
WO1995003413A1 (en) * 1993-07-23 1995-02-02 The Rockefeller University High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins
WO1997005899A3 (en) * 1995-08-04 1997-05-29 Univ Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO1997046582A1 (en) * 1996-06-05 1997-12-11 Peptide Therapeutics Limited Meningococcal vaccine
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1999061053A1 (en) * 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
WO2000012535A3 (en) * 1998-09-01 2000-06-08 Antex Biolog Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2000042193A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
EP1069133A1 (en) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
WO2001004316A3 (en) * 1999-07-14 2001-08-09 Chiron Spa Antigenic meningococcal peptides
WO2001038350A3 (en) * 1999-11-29 2001-11-15 Chiron Spa 85kDa NEISSERIAL ANTIGEN
US6350449B1 (en) 1995-06-07 2002-02-26 Baxter International Inc. Antibodies to meningococcal polysaccharide conjugate vaccines
US6355253B1 (en) 1993-05-13 2002-03-12 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
WO2003051379A1 (en) * 2001-12-17 2003-06-26 Health Protection Agency Outer membrane vesicles from gram negative bacteria and use as a vaccine
EP1355673A2 (en) 2001-01-23 2003-10-29 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
US6642354B2 (en) * 1996-08-27 2003-11-04 Chiron Corporation Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
EP1297844A3 (en) * 1998-11-02 2004-01-14 Health Protection Agency Multicomponent meningococcal vaccine
EP0854729B1 (en) * 1995-09-18 2004-03-10 United States Army Medical Research Materiel Command (USAMRMC) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6861507B1 (en) * 1998-07-10 2005-03-01 University Of Nottingham Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
EP1252182A4 (en) * 2000-01-25 2005-03-02 Univ Queensland PRESERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NHHA CONTAINING PROTEINS
WO2005042564A1 (en) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Flagellin fusion proteins as adjuvants or vaccines and methods of use
US6916478B2 (en) 1995-08-04 2005-07-12 University Of Guelph Vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
AU2003213540B2 (en) * 1998-05-29 2006-01-05 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
US7029684B1 (en) * 1997-01-24 2006-04-18 Allan William Cripps Antigenic composition of a Pseudomonas aeruginosa
EP1741443A3 (en) * 1998-05-29 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
US7238345B1 (en) 1988-12-19 2007-07-03 Wyeth Holdings Corporation Recombinant microorganism expressing meningococcal class 1 outer membrane protein
EP1774977A3 (en) * 1999-08-03 2007-07-04 GlaxoSmithKline Biologicals S.A. Genetically engineered bleb vaccine
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
US7604810B2 (en) 1999-04-30 2009-10-20 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
US7700755B2 (en) 1992-03-02 2010-04-20 Novartis Vaccines And Diagnostics S. R. L. Helicobacter pylori CAI antigen
WO2009144462A3 (en) * 2008-05-28 2010-04-29 The University Of Nottingham Laminin receptor binding proteins
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
US7786255B2 (en) 2004-04-21 2010-08-31 The Bringham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
EP2258389A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2279747A1 (en) 2004-10-29 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Immunogenic bacterial vesicles with outer membrane proteins
US7901907B2 (en) 1996-01-04 2011-03-08 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Process for production of Helicobacter pylori bacterioferritin
US7989162B2 (en) 2002-02-07 2011-08-02 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8034349B2 (en) 2006-06-15 2011-10-11 Giuseppe Teti Peptides that mimic non-human cross-reactive protective epitopes of the group B meningococcal capsular polysaccharide
US8114960B2 (en) 2000-02-28 2012-02-14 Novartis Ag Heterologous expression of Neisserial proteins
US20120156236A1 (en) * 1998-05-01 2012-06-21 Novartis Ag Neisseria meningitidis antigens and compositions
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US20120328643A1 (en) * 2000-01-17 2012-12-27 Novartis Ag Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
US8367317B2 (en) 2005-04-08 2013-02-05 Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8492364B2 (en) 2008-07-21 2013-07-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides
US8592143B2 (en) 2002-04-12 2013-11-26 Abl Sa Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US8753651B2 (en) 2001-06-20 2014-06-17 Novartis Ag Capsular polysaccharide solubilisation and combination vaccines
EP1322328B1 (en) * 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US8968748B2 (en) 2005-01-27 2015-03-03 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US9011869B2 (en) 2001-09-06 2015-04-21 Glaxosmithkline Biologicals Sa Hybrid and tandem expression of Neisserial proteins
USRE45587E1 (en) 2001-07-26 2015-06-30 Glaxosmithkline Biologicals Sa Vaccines comprising aluminum adjuvants and histidine
US20160051658A1 (en) * 1999-10-29 2016-02-25 Glaxosmithkline Biologicals Sa Neisserial antigenic peptides
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
US9636393B2 (en) 1999-11-29 2017-05-02 Glaxosmithkline Biologicals Sa Compositions comprising Neisseria meningitidis antigens from serogroups B and C
EP3174552A4 (en) * 2014-07-30 2018-02-28 Cleveland Biolabs, Inc. Flagellin-based agents and uses including effective vaccination
US10179167B2 (en) 2010-09-10 2019-01-15 Glaxosmithkline Biologicals S.A. Developments in meningococcal outer membrane vesicles
US10195264B2 (en) 2004-04-22 2019-02-05 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
WO2022060905A1 (en) * 2020-09-15 2022-03-24 The University Of Montana Compositions and methods targeting filamentous bacteriophage
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401569T4 (en) * 1999-12-28 2004-07-21 Akzo Nobel N.V. Salmonelle vaccine that does not cause antibodies to flagelin or flagelle
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (en) 2003-01-30 2014-05-19 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CN102356089B (en) 2008-02-21 2014-02-19 诺华股份有限公司 Meningococcal fHBP polypeptide
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
JP2012090571A (en) * 2010-10-27 2012-05-17 Sekisui Chem Co Ltd Method for immunizing animal, composition for immunization, method for producing antibody, and method for producing hybridoma
JP6786394B2 (en) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Modified Neisseria meningitidis fHbp polypeptide
ES2762481T3 (en) * 2014-04-17 2020-05-25 Corning Inc Cell culture container and its use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
WO1983003354A1 (en) * 1982-03-30 1983-10-13 Us Army Neisseria gonorrhoeae vaccine
EP0145359B1 (en) * 1983-11-21 1991-01-16 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
JPH01125328A (en) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados Meningococcus vaccine
ATE121782T1 (en) * 1988-05-05 1995-05-15 Praxis Biolog Inc RECOMBINANT VACCINE OF FLAGELLIN.

Cited By (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238345B1 (en) 1988-12-19 2007-07-03 Wyeth Holdings Corporation Recombinant microorganism expressing meningococcal class 1 outer membrane protein
US5773007A (en) * 1990-09-17 1998-06-30 National Research Council Of Canada Vaccine compositions
WO1992004915A1 (en) * 1990-09-17 1992-04-02 North American Vaccine, Inc. Improved vaccine compositions
US7700755B2 (en) 1992-03-02 2010-04-20 Novartis Vaccines And Diagnostics S. R. L. Helicobacter pylori CAI antigen
WO1994008021A1 (en) * 1992-10-02 1994-04-14 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Immunogenic meningococcal lps and outer membrane vesicles and vaccine therefrom
US5705161A (en) * 1992-10-02 1998-01-06 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Immunogenic meningococcal LPS and other membrane vesicles and vaccine therefrom
WO1994009822A1 (en) * 1992-10-26 1994-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNIZATION AGAINST NEISSERIA GONORRHOEAE AND $i(NEISSERIA MENINGITIDIS)
US6355253B1 (en) 1993-05-13 2002-03-12 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
US6921537B2 (en) 1993-05-13 2005-07-26 Wyeth Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
US6013267A (en) * 1993-07-23 2000-01-11 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5879686A (en) * 1993-07-23 1999-03-09 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1995003413A1 (en) * 1993-07-23 1995-02-02 The Rockefeller University High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6350449B1 (en) 1995-06-07 2002-02-26 Baxter International Inc. Antibodies to meningococcal polysaccharide conjugate vaccines
US6916478B2 (en) 1995-08-04 2005-07-12 University Of Guelph Vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO1997005899A3 (en) * 1995-08-04 1997-05-29 Univ Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
EP0854729B1 (en) * 1995-09-18 2004-03-10 United States Army Medical Research Materiel Command (USAMRMC) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US7901907B2 (en) 1996-01-04 2011-03-08 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Process for production of Helicobacter pylori bacterioferritin
WO1997046582A1 (en) * 1996-06-05 1997-12-11 Peptide Therapeutics Limited Meningococcal vaccine
US7504254B2 (en) 1996-08-27 2009-03-17 Novartis Vaccines And Diagnostics, Inc. Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
US6642354B2 (en) * 1996-08-27 2003-11-04 Chiron Corporation Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
US7063949B2 (en) 1996-08-27 2006-06-20 Chiron Corporation Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
US7029684B1 (en) * 1997-01-24 2006-04-18 Allan William Cripps Antigenic composition of a Pseudomonas aeruginosa
US7371394B2 (en) 1997-01-24 2008-05-13 Auspharm International Limited Antigenic composition of a Pseudomonas aeruginosa protein
US20120156236A1 (en) * 1998-05-01 2012-06-21 Novartis Ag Neisseria meningitidis antigens and compositions
US20160030545A1 (en) * 1998-05-01 2016-02-04 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US9139621B2 (en) 1998-05-01 2015-09-22 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
AU2003213540B8 (en) * 1998-05-29 2006-09-28 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
WO1999061053A1 (en) * 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
AU2003213540B2 (en) * 1998-05-29 2006-01-05 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
EP1741443A3 (en) * 1998-05-29 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
EP2796148A3 (en) * 1998-05-29 2015-02-25 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
US8007815B1 (en) 1998-05-29 2011-08-30 Novartis Ag Combination meningitidis B/C vaccines
AU761495B2 (en) * 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
US6861507B1 (en) * 1998-07-10 2005-03-01 University Of Nottingham Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
US8663654B2 (en) 1998-07-15 2014-03-04 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
WO2000012535A3 (en) * 1998-09-01 2000-06-08 Antex Biolog Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6821521B1 (en) 1998-11-02 2004-11-23 Health Protection Agency Multicomponent meningococcal vaccine
EP1297844A3 (en) * 1998-11-02 2004-01-14 Health Protection Agency Multicomponent meningococcal vaccine
EP2248535A1 (en) * 1998-11-02 2010-11-10 Health Protection Agency Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
US6797273B1 (en) 1999-01-15 2004-09-28 Glaxosmithkline Biologicals S.A. Neisseria meningitidis antigen
WO2000042193A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
US9169301B2 (en) 1999-04-30 2015-10-27 Glaxosmithkline Biologicals Sa Conserved Neisserial antigens
US7604810B2 (en) 1999-04-30 2009-10-20 Novartis Vaccines And Diagnostics Srl Conserved Neisserial antigens
US7422754B2 (en) 1999-07-13 2008-09-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
EP1069133A1 (en) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis compounds and anti-infection applications thereof
WO2001004150A3 (en) * 1999-07-13 2001-12-13 Inst Nat Sante Rech Med Neisseria meningitidis compounds and anti-infection applications thereof
EP1935979A3 (en) * 1999-07-14 2008-09-17 Novartis Vaccines and Diagnostics S.r.l. Antigenic meningococcal peptides
US7618636B1 (en) 1999-07-14 2009-11-17 Novartis Vaccines And Diagnostics Srl Antigenic meningococcal peptides
WO2001004316A3 (en) * 1999-07-14 2001-08-09 Chiron Spa Antigenic meningococcal peptides
EP1774977A3 (en) * 1999-08-03 2007-07-04 GlaxoSmithKline Biologicals S.A. Genetically engineered bleb vaccine
US20160051658A1 (en) * 1999-10-29 2016-02-25 Glaxosmithkline Biologicals Sa Neisserial antigenic peptides
US9636393B2 (en) 1999-11-29 2017-05-02 Glaxosmithkline Biologicals Sa Compositions comprising Neisseria meningitidis antigens from serogroups B and C
EP1741784A1 (en) * 1999-11-29 2007-01-10 Chiron SRL 85kDa neisserial antigen
WO2001038350A3 (en) * 1999-11-29 2001-11-15 Chiron Spa 85kDa NEISSERIAL ANTIGEN
US7700119B2 (en) 1999-11-29 2010-04-20 Novartis Vaccines And Diagnostics Srl 85kDa neisserial antigen
US20160030546A1 (en) * 2000-01-17 2016-02-04 Glaxosmithkline Biologicals Sa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
US20120328643A1 (en) * 2000-01-17 2012-12-27 Novartis Ag Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
US8383790B2 (en) 2000-01-25 2013-02-26 The University Of Queensland Modified surface antigen
US7947291B2 (en) 2000-01-25 2011-05-24 The University Of Queensland Modified surface antigen
US8367070B2 (en) 2000-01-25 2013-02-05 The University Of Queensland Modified surface antigen
EP1252182A4 (en) * 2000-01-25 2005-03-02 Univ Queensland PRESERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NHHA CONTAINING PROTEINS
EP2395013A3 (en) * 2000-01-25 2012-03-21 The University of Queensland Proteins comprising conserved regions of Neisseria meningitidis surface antigen NhhA
CN102417537A (en) * 2000-01-25 2012-04-18 昆士兰大学 Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
US9267163B2 (en) 2000-02-28 2016-02-23 Glaxosmithkline Biologicals Sa Hybrid expression of neisserial proteins
US8703914B2 (en) 2000-02-28 2014-04-22 Novartis Ag Heterologous expression of neisserial proteins
US8114960B2 (en) 2000-02-28 2012-02-14 Novartis Ag Heterologous expression of Neisserial proteins
EP1322328B1 (en) * 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US8980285B2 (en) 2000-07-27 2015-03-17 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against Neisseria meningitidis
EP2332581A1 (en) * 2001-01-23 2011-06-15 Aventis Pasteur Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
US8999354B2 (en) 2001-01-23 2015-04-07 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US9173955B2 (en) 2001-01-23 2015-11-03 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
EP1355673A2 (en) 2001-01-23 2003-10-29 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
EP2957300A3 (en) * 2001-01-23 2016-03-30 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US9844601B2 (en) 2001-01-23 2017-12-19 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US10143757B2 (en) 2001-01-23 2018-12-04 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US10617766B2 (en) 2001-01-23 2020-04-14 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US8741314B2 (en) 2001-01-23 2014-06-03 Sanofi Pasteur, Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US8734813B2 (en) 2001-01-23 2014-05-27 Sanofi Pasteur, Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US8722062B2 (en) 2001-01-23 2014-05-13 Sanofi Pasteur, Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
US8889152B2 (en) 2001-06-20 2014-11-18 Novartis Ag Capsular polysaccharides solubilisation and combination vaccines
US9782467B2 (en) 2001-06-20 2017-10-10 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
US10716841B2 (en) 2001-06-20 2020-07-21 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
US9452207B2 (en) 2001-06-20 2016-09-27 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
US8753651B2 (en) 2001-06-20 2014-06-17 Novartis Ag Capsular polysaccharide solubilisation and combination vaccines
US9358278B2 (en) 2001-06-20 2016-06-07 Novartis Ag Capsular polysaccharide solubilisation and combination vaccines
US8852606B2 (en) 2001-06-20 2014-10-07 Novartis Ag Capsular polysaccharide solubilisation and combination vaccines
US9782466B2 (en) 2001-06-20 2017-10-10 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
USRE45587E1 (en) 2001-07-26 2015-06-30 Glaxosmithkline Biologicals Sa Vaccines comprising aluminum adjuvants and histidine
US9011869B2 (en) 2001-09-06 2015-04-21 Glaxosmithkline Biologicals Sa Hybrid and tandem expression of Neisserial proteins
US7384645B2 (en) 2001-12-17 2008-06-10 Health Protection Agency Outer membrane vesicles from gram negative bacteria and use as a vaccine
AU2002350974B2 (en) * 2001-12-17 2006-03-02 Health Protection Agency Outer membrane vesicles from gram negative bacteria and use as a vaccine
WO2003051379A1 (en) * 2001-12-17 2003-06-26 Health Protection Agency Outer membrane vesicles from gram negative bacteria and use as a vaccine
US7989162B2 (en) 2002-02-07 2011-08-02 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8211633B2 (en) 2002-02-07 2012-07-03 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8592143B2 (en) 2002-04-12 2013-11-26 Abl Sa Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
US9702005B2 (en) 2002-04-12 2017-07-11 Abl Sa Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
EP2258390A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2258388A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
EP2258389A1 (en) 2002-08-30 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Improved bacterial outer membrane vesicles
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
WO2005042564A1 (en) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Flagellin fusion proteins as adjuvants or vaccines and methods of use
US10906962B2 (en) 2004-04-21 2021-02-02 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US8350017B2 (en) 2004-04-21 2013-01-08 The Brigham And Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US8912314B2 (en) 2004-04-21 2014-12-16 The Brigham And Woman's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US10017563B2 (en) 2004-04-21 2018-07-10 The Brigham And Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US8410249B2 (en) 2004-04-21 2013-04-02 The Brigham And Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US8435515B2 (en) 2004-04-21 2013-05-07 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US9458227B2 (en) 2004-04-21 2016-10-04 The Brigham And Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US7786255B2 (en) 2004-04-21 2010-08-31 The Bringham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US8461319B2 (en) 2004-04-21 2013-06-11 Beth Israel Deaconess Medical Center, Inc. Poly-n-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US8084595B2 (en) 2004-04-21 2011-12-27 The Brigham And Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US10195264B2 (en) 2004-04-22 2019-02-05 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
EP2279747A1 (en) 2004-10-29 2011-02-02 Novartis Vaccines and Diagnostics S.r.l. Immunogenic bacterial vesicles with outer membrane proteins
US9452208B2 (en) 2005-01-27 2016-09-27 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US10478484B2 (en) 2005-01-27 2019-11-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US11801293B2 (en) 2005-01-27 2023-10-31 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US8968748B2 (en) 2005-01-27 2015-03-03 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US10857221B2 (en) 2005-01-27 2020-12-08 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US10046043B2 (en) 2005-01-27 2018-08-14 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US8367317B2 (en) 2005-04-08 2013-02-05 Melbourne Health; St. Vincent's Hospital Melbourne; Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US9701982B2 (en) 2005-04-08 2017-07-11 Abl Sa Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8034349B2 (en) 2006-06-15 2011-10-11 Giuseppe Teti Peptides that mimic non-human cross-reactive protective epitopes of the group B meningococcal capsular polysaccharide
WO2009144462A3 (en) * 2008-05-28 2010-04-29 The University Of Nottingham Laminin receptor binding proteins
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
US10034927B2 (en) 2008-07-21 2018-07-31 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US8492364B2 (en) 2008-07-21 2013-07-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides
US11123416B2 (en) 2008-07-21 2021-09-21 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US9474806B2 (en) 2008-07-21 2016-10-25 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US10179167B2 (en) 2010-09-10 2019-01-15 Glaxosmithkline Biologicals S.A. Developments in meningococcal outer membrane vesicles
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2015296298B2 (en) * 2014-07-30 2020-05-21 Genome Protection, Inc. Flagellin-based agents and uses including effective vaccination
EP3174552A4 (en) * 2014-07-30 2018-02-28 Cleveland Biolabs, Inc. Flagellin-based agents and uses including effective vaccination
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2022060905A1 (en) * 2020-09-15 2022-03-24 The University Of Montana Compositions and methods targeting filamentous bacteriophage

Also Published As

Publication number Publication date
DE68921895T2 (en) 1995-09-07
EP0449958B9 (en) 2003-05-28
AU4821990A (en) 1990-07-10
FI912965A0 (en) 1991-06-18
ES2070312T3 (en) 1995-06-01
DK175788B1 (en) 2005-02-21
WO1990006696A3 (en) 1990-07-12
DK117491A (en) 1991-08-15
FI113009B (en) 2004-02-27
DK117491D0 (en) 1991-06-18
JPH06503465A (en) 1994-04-21
EP0449958B2 (en) 2002-11-13
EP0449958A1 (en) 1991-10-09
ATE120093T1 (en) 1995-04-15
NO912369L (en) 1991-08-06
ES2070312T5 (en) 2003-05-16
DE68921895T3 (en) 2003-05-22
JP3436756B2 (en) 2003-08-18
NO912369D0 (en) 1991-06-18
AU640118B2 (en) 1993-08-19
EP0449958B1 (en) 1995-03-22
NO305463B1 (en) 1999-06-07
DE68921895D1 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
EP0449958B1 (en) Meningococcal class 1 outer-membrane protein vaccine
US7118757B1 (en) Meningococcal class 1 outer-membrane protein vaccine
AU648251B2 (en) Vaccines for nontypable haemophilus influenzae
JP4827196B2 (en) Domains and epitopes of meningococcal protein NMB1870
CA2215161C (en) Proteinase k resistant surface protein of neisseria meningitidis
US7786286B2 (en) Proteinase K resistant surface protein of Neisseria meningitidis
CA2512917A1 (en) Methods for increasing neisseria protein expression
KR960016208B1 (en) Vaccines and diagnostic assays for haemophilus influenzae
van der Ley et al. Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis
AU631378B2 (en) Vaccines and diagnostic assays for haemophilus influenzae
AU744733B2 (en) Neisseria lactoferrin binding protein
CA2007248C (en) Meningococcal class 1 outer-membrane protein vaccine
US5196338A (en) Recombinant vectors for Haemophilus influenzae peptides and proteins
Blake et al. Developing a gonococcal protein I vaccine
AU695173B2 (en) Novel opacity associated proteins, DNA encoding the same, and methods of use thereof
Reyes et al. MOLECULAR ANALYSIS OF Neisseria meningitidis CLASS 3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990901397

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 912965

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1990901397

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990901397

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 912965

Country of ref document: FI